This Article Free upon publication Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waxman, S. Articles by Muller, J. E. Search for Related Content PubMed PubMed Citation Articles by Waxman, S. Articles by Muller, J. E. Related Collections Other arteriosclerosis

(Circulation. 2006;114:2390-2411.)
© 2006 American Heart Association, Inc.

New Drugs and Technologies

Detection and Treatment of Vulnerable Plaques and Vulnerable Patients

Novel Approaches to Prevention of Coronary Events

Sergio Waxman, MD; Fumiyuki Ishibashi, MD; James E. Muller, MD

From the Department of Cardiovascular Medicine, Lahey Clinic, Burlington, Mass (S.W., F.I.); Tufts University School of Medicine, Boston, Mass (S.W.); and Cardiovascular Division, Massachusetts General Hospital and Harvard Medical School, Boston, Mass (J.E.M.).

Correspondence to Dr Sergio Waxman, Lahey Clinic, 41 Mall Rd, Burlington, MA 01805. E-mail Sergio.Waxman{at}lahey.org

Key Words: coronary diseasecoronary imaging • prevention • plaque

	Introduction

Top Introduction Vulnerable Plaque Methods to Image Vulnerable... Potential Treatment of... Conclusions References

 
There is growing interest in the possibility that identification and treatment of vulnerable plaques and vulnerable patients can enhance the progress made against coronary artery disease. Innovations in medical therapy—statins and other agents—and novel interventional cardiology techniques—eg, drug-eluting stents—have significantly decreased the morbidity and mortality caused by coronary atherosclerosis. However, coronary events continue to be the leading cause of death in the United States, accounting for >479 000 deaths (1 in 5) in 2003.¹

Improved preventive measures are needed because, for many individuals, sudden coronary death is the first sign of the disorder. And even those who survive an acute coronary syndrome remain at high risk. After successful treatment of the initial culprit lesion by a percutaneous coronary intervention (PCI), the risk of a coronary event from a new lesion is 10% in the following year and 5% in each of the subsequent 4 years^2,3 (Figure 1).

View larger version (15K): [in this window] [in a new window]   Figure 1. Occurrence of coronary events (revascularization, death, MI, acute coronary syndromes, or congestive heart failure) after PCI in 4 studies of bare-metal stents. In addition to events resulting from stented lesions (solid line), many events are caused by nontarget (vulnerable) plaques (dashed line). Modified from Cutlip et al2 with permission from the American Heart Association. Copyright 2004.

These substantial levels of ongoing morbidity and mortality have led to heightened interest in new methods to prevent coronary events. For primary prevention, the effort has focused on plasma markers and noninvasive testing to identify vulnerable individuals. For secondary prevention, interest has focused on vulnerable patients and the vulnerable plaques they may possess that might be identified and treated during the catheterization for their initial event.

	Vulnerable Plaque

Top Introduction Vulnerable Plaque Methods to Image Vulnerable... Potential Treatment of... Conclusions References

 
Definitions of the Vulnerable Plaque and the Vulnerable Patient
The terminology to describe vulnerability has become relatively standardized.^4–10 The term "vulnerable plaque" is used to designate a plaque at high risk of disruption leading to thrombosis. "High-risk plaque" and "thrombosis-prone plaque" are used as synonyms for "vulnerable plaque."

Although prospective evidence from natural history studies is not yet available, retrospective autopsy studies suggest that there are several histological types of vulnerable plaque.⁶ The most common type of suspected vulnerable plaque is an inflamed thin-cap fibroatheroma (TCFA), which is thought to account for 60% to 70% of coronary events (Figure 2). An additional 30% to 40% of events, particularly in younger women, occur at proteoglycan-rich erosion sites.¹¹

View larger version (65K): [in this window] [in a new window]   Figure 2. Culprit and suspected vulnerable atherosclerotic lesions. A, Cross section of a coronary artery from a patient who died of a MI. An occlusive thrombus overlies a ruptured (arrows) TCFA. B, High-power magnification. The contents of the atheromatous plaque have led to thrombosis. Courtesy of Dr E. Falk. C, Molecular and cellular inflammatory processes contributing to TCFA formation and rupture. T lymphocytes, macrophages, and mast cells all contribute to the inflammatory reaction associated with the accumulation of oxidized LDL and microvascular hemorrhage. Proteases may weaken the cap, leading to rupture and thrombosis. Modified from Hansson23 with permission from the Massachusetts Medical Society. Copyright 2005. D, TCFA detected in a longitudinal section of a human coronary artery autopsy specimen. A thin fibrous cap (small arrow) covers a relatively large lipid pool and necrotic core (large arrow). Courtesy of InfraReDx, Inc.

Most vulnerable plaque detection devices in development are designed to detect TCFAs. Because these devices will not detect erosion sites in advance, their sensitivity for predicting cardiac events will be limited. Specificity of a TCFA detector for predicting plaque rupture will also be limited because not all TCFAs will rupture, nor will all ruptures lead to a cardiac event.

Hence, the term "vulnerable patient" has been introduced to indicate an individual with a high likelihood of experiencing a cardiac event. Such a patient is likely to have vulnerable blood (prone to thrombosis), vulnerable myocardium (prone to arrhythmia), and 1 vulnerable plaque. To enhance primary prevention, a search is underway for novel methods to identify vulnerable patients.⁷ Because a vulnerable plaque is likely to be the root cause of vulnerability of the patient and may be amenable to systemic or local therapy, the search for the vulnerable patient of necessity is closely linked to efforts to identify vulnerable plaques.

Systemic and Focal Manifestations of Atherosclerosis
There is considerable discussion about the relative effort that should be devoted to combating the systemic versus focal manifestations of atherosclerosis.^12–15 If the systemic features of the disease are dominant, efforts to detect and treat vulnerable plaques are unlikely to yield significant benefits. In such a scenario, numerous vulnerable plaques would be present, and local treatment would not be feasible. Even if relatively few vulnerable plaques developed, they could appear rapidly, presumably in response to a systemic inflammatory stimulus, and thereby thwart attempts at local treatment, which could be administered only during cardiac catheterization.

The presence of plaques in many vascular beds as documented in autopsy studies, the diffuse inflammatory involvement sometimes observed in the coronary tree, and the appearance of >1 disrupted plaque in many patients with an acute coronary syndrome confirm the systemic nature of the disease.¹⁶

However, there is also evidence that the lesions causing clinical events are focal. Interventional cardiologists generally find that a single location is responsible for an acute coronary event. Hence, most agree that atherosclerosis is a systemic disease with focal manifestations.

There is uncertainty, however, over the diffuse versus focal nature of risk in the coronary arteries. If TCFAs are considered to be precursors of culprit lesions, as many believe they are, then risk is quite focal because TCFAs are focal structures. Kolodgie et al¹⁷ found an incidence of only 1.3±1.4 TCFAs per heart in patients dying of sudden cardiac death despite the widespread presence of less advanced—and presumably lower-risk—atherosclerotic lesions. Hence, TCFAs, the sites suspected to be at highest risk, are often single, and when more than one is present, they are at most "oligofocal." It has also been noted that risk is concentrated in the proximal portions of the coronary arteries¹⁸ where focal areas of low shear stress may predispose to formation of vulnerable plaques.^19,20

Thus, there is sufficient evidence supporting the focality of risk to test the hypothesis that local diagnosis and treatment of vulnerable plaques may be of clinical value. The importance of the local treatment of flow-limiting stenoses has already been demonstrated and is the basis for the millions of PCI and CABG procedures performed each year. The clinical value of its preventive counterpart, the local detection and treatment of vulnerable, noncritical stenoses, is currently unknown.

Pathophysiology of Vulnerable Plaque Formation
There has been considerable progress in the identification of the molecular and cellular processes causing atherosclerosis and its clinical sequelae.^21,22 LDL cholesterol is central to the development of the disease. In addition, it is now clearly established that inflammation plays an important role in the initiation of lesions and is likely to be responsible for the activation of the disease in more than a single plaque or artery.^23,24 Many of the processes leading to the formation of localized, inflamed TCFAs are now understood^23,24 (Figure 2C). These presumably dangerous, highly focal, and well-differentiated structures result from an interplay of the accumulation of oxidized LDL in the arterial wall and the actions of macrophages, which are strongly influenced by T lymphocytes.²⁵

Studies in genetically engineered mice deficient in apolipoprotein E (apoE), which develop advanced plaques similar to those in patients, have increased our understanding of certain clinical observations. ACE inhibitors prevent myocardial infarction (MI) in patients, but the mechanism has been unclear. In the apoE mouse, it was found that increased levels of endogenous angiotensin II are associated with increased TCFA formation.²⁶ An increase in T-helper type 1–like lymphocytes also promoted TCFA occurrence, indicating a possible role of the T-helper switch in the formation of these presumably vulnerable plaques.

Eriksson²⁷ also used the apoE^–/– mouse to study the mechanism of leukocyte recruitment into TCFAs. It was found that both platelet factor 4 and RANTES (a protein cytokine) play roles in leukocyte recruitment and that blockage of RANTES leads to decreased atherosclerosis.

The apoE^–/– mouse has also been used to study apoptosis, which is a prominent feature of plaques that cause sudden coronary deaths in patients.²⁸ ApoE^–/– mice transfected with the Fas ligand, which promotes apoptosis, showed more frequent signs of vulnerability (ruptured plaques, intraplaque hemorrhages, buried caps, and iron deposits) than nontransfected mice.²⁹ There was a 3-fold increase in the amount of apoptosis in the caps covering plaques in transfected versus nontransfected mice. Michowitz et al³⁰ reported that the tumor necrosis factor–related apoptosis-inducing ligand was increased in plaques with necrotic cores in both animal and human specimens. Tumor necrosis factor–related apoptosis-inducing ligand also colocalized with oxidized LDL, suggesting a mechanism by which infiltration of LDL might increase cell death and lead to the formation of necrotic cores.

Sluijter et al³¹ studied matrix metalloproteinases, which can degrade cap constituents, and an extracellular matrix metalloproteinase inducer in carotid endarterectomy specimens. Increased activity of matrix metalloproteinases 8 and 9 was associated with an inflammatory plaque phenotype, and different glycosylation forms of extracellular matrix metalloproteinase inducer were associated with varying degrees of matrix metalloproteinase activity. It was concluded that extracellular matrix metalloproteinase inducer glycosylation may play a role in plaque destabilization.

Vascular and hemodynamic forces are also likely to play a role in the formation and rupture of TCFAs. Stone et al¹⁹ and Slager et al²⁰ demonstrated that areas of low shear stress predispose to the formation of advanced plaques, presumably by creating conditions that favor transmigration of lipids and inflammatory cells into the vessel wall. High shear stress, on the other hand, can promote plaque rupture and platelet aggregability, leading to an occlusive thrombotic event.^19,20

Moreno et al³² reported that, in human aortic plaques, microvessel density is increased in lesions with inflammation, intraplaque hemorrhage, and TCFAs, suggesting that neovascularization contributes to TCFA formation and rupture. Kolodgie et al³³ demonstrated increased hemorrhage, presumably from similar microvessels, in necrotic cores of coronary plaques of patients who died suddenly. Such hemorrhage would add to the lipid content of the plaque because erythrocytes are cholesterol rich.

Plasma Markers of Vulnerability
Increased understanding of the processes causing atherosclerosis has facilitated efforts to identify novel markers of risk that may be circulating in plasma and readily available for sampling. Plasma markers of risk that improve the accuracy provided by cholesterol determinations would enhance primary prevention in the general population by identifying individuals in need of further diagnostic testing and would improve secondary prevention by guiding therapy in patients known to have coronary disease.

High-sensitivity C-reactive protein (hs-CRP), the most extensively studied plasma marker of inflammation, identifies an increased risk of an acute coronary event independent of LDL cholesterol.³⁴ Statin therapy, which prevents cardiac events, also decreases hs-CRP levels.^35,36 A large randomized trial is in progress to determine whether statin therapy can prevent coronary events in patients with an elevated hs-CRP and normal LDL cholesterol levels.³⁷

Lipoprotein-associated phospholipase A2, another plasma marker associated with inflammation, is an independent predictor of cardiac events.³⁸ Nuclear factor-B, which controls nuclear processes associated with inflammation, is increased in patients with unstable angina.³⁹ Advances in genetics are already producing markers of vulnerability to coronary events. A markedly beneficial effect of a relatively rare mutation in the gene encoding a protease (proprotein convertase subtilisin/kexin type 9 serine protease) affecting plasma LDL levels was recently reported.⁴⁰ The 2.6% of black subjects who had this beneficial mutation had an 88% reduction in coronary disease over a 15-year follow-up. Although this marker is useful for only a few, the finding supports the hypothesis that genetic plasma markers will eventually improve the identification of protected and vulnerable individuals in the general population.

	Methods to Image Vulnerable Plaques and Vulnerable Patients

Top Introduction Vulnerable Plaque Methods to Image Vulnerable... Potential Treatment of... Conclusions References

 
Although sampling of peripheral blood to assess vulnerability has the advantages of ease of use and low cost, imaging the actual extent of atherosclerosis in vessels provides improved risk stratification.⁴¹ For primary prevention, emphasis is on noninvasive imaging of vessels in those deemed to be at higher risk after initial assessment with demographic characteristics and plasma markers. For secondary prevention in patients already undergoing catheterization, invasive imaging can be performed with minimal added risk and cost and has considerable advantages over noninvasive imaging.

Although noninvasive imaging of coronary plaque would be of greatest value, it is quite challenging because of the small size, location, and motion of the coronary arteries. Hence, most efforts to perform noninvasive identification of vulnerable plaques have focused on the carotid arteries, which are larger, closer to the surface, and not in motion.

Noninvasive Methods to Image Vulnerable Plaques in the Carotid Arteries
Four technologies are under study as methods to identify vulnerable carotid plaque: ultrasound, MRI, nuclear imaging, and x-ray multidetector computed tomography (MDCT).^42,43 Such methods benefit from the accessibility of carotid plaques and the availability of tissue obtained after carotid endarterectomy to serve as the gold standard for the assessment of imaging results.

Ultrasonic imaging is the method most frequently used in clinical practice to evaluate carotid plaques. Although most clinical decision making is based exclusively on symptomatic status and the degree of stenosis detected, plaques that are hypoechoic or show signs of disruption have been reported to carry an increased risk of stroke.⁴⁴

Carotid ultrasound is also used as a research tool because individuals with increased intima-media thickness have been found to be at increased risk of coronary events.⁴⁵ However, the predictive value of intima-media thickness findings is relatively limited for use in individual patients. This limitation, plus the inability of ultrasound to precisely identify different types of tissue, has led to research with other technologies.

MRI, which can readily identify lipid-rich tissue, has been used to identify potentially vulnerable carotid plaques. Four studies have identified a close relationship between MRI signs of vulnerability and histological findings.^46–49 Ruberg et al⁵⁰ used proton MR spectroscopy to enhance the ability of conventional MR to identify the chemical composition of tissue. Ex vivo spectroscopy was performed in carotid samples with an 11.7-T magnet. Peaks indicating the presence of cholesteryl esters were 5.5% of the signal obtained in a lipid-rich area (by MRI) versus 0.9% in a lipid-poor area. The authors conclude that image-guided proton MR spectroscopy may permit noninvasive detection and quantification of cholesteryl ester in atherosclerotic plaques in vivo.

Although the MRI results are promising, nuclear imaging methods have a greater ability to identify metabolic processes such as those associated with inflammation. Davies et al⁵¹ used PET to study fluorodeoxyglucose uptake as an index of macrophage activity in patients undergoing carotid endarterectomy for transient ischemic attacks. Fluorodeoxyglucose uptake was more likely to be increased at the site of a stenosis. Tawakol et al⁵² demonstrated an excellent correlation between in vivo fluorodeoxyglucose-PET signals obtained preoperatively and the macrophage content of carotid plaques assessed by histological examination after carotid endarterectomy. The use of MDCT for plaque analysis is limited because of the lack of sufficient contrast between lipid and fibrotic components and because of the radiation exposure required. CT, which has been coupled with PET in the new PET/CT devices, is useful for providing anatomic orientation of the PET signal, which has poor spatial resolution.

Despite these advances in imaging, current clinical decision making for the management of carotid artery disease remains stenosis based and similar to that for coronary artery disease. Further studies are needed to confirm the linkage of findings suggesting vulnerability to cerebral events and to determine whether treatment (endarterectomy, stenting, or intensified systemic therapy) of plaques guided by supplemental information about vulnerability is superior to conventional management.

Noninvasive Methods to Image Vulnerable Plaques in the Coronary Arteries
As noted, significant obstacles must be overcome to reach the highly desirable goal of noninvasively identifying vulnerable plaques in the coronary arteries.

MDCT, with its rapid acquisition times (to overcome motion) and relatively high spatial resolution, has achieved the greatest success in noninvasive evaluation of coronary arteries.^53–55 CT methods can assess the degree of coronary artery calcification, which adds prognostic information beyond that provided by the Framingham Risk Score.^56,57 However, detection of calcification differs from detection of vulnerable plaques, which may not be calcified.⁵⁸

New MDCT instruments can detect coronary artery stenoses noninvasively,⁵⁹ but characterization of the composition of plaques (beyond detection of calcium) is not yet possible (Figure 3). Identification of lipid-rich plaques is hampered by the lack of major differences in opacity between lipid-rich and fibrotic plaques. Nevertheless, Kunimasa et al⁶⁰ were able to identify differences in the MDCT appearance of plaques in a group of patients with an acute coronary syndrome compared with findings in a group of patients with stable angina. It seems likely that MDCT will identify "suspected" vulnerable plaque that will in many cases lead to more intensive study of the lesion at cardiac catheterization with one of the many invasive methods under development.

View larger version (81K): [in this window] [in a new window]   Figure 3. Visualization of coronary plaque by 64-slice MDCT. A, Multiplanar reconstruction of the proximal left anterior descending artery. Plaque with expansive remodeling is present (large arrow). Calcification is present distal to the lesion (small arrow). B, Cross-sectional view at the site of maximum plaque area by MDCT demonstrates the contrast-enhanced lumen and the eccentric plaque (arrow). Modified from Achenbach and Daniel55 with permission from The American College of Cardiology Foundation. Copyright 2005.

MRI has also been used for noninvasive characterization of coronary plaques (Figure 4).⁶¹ Unfortunately, the length of time required for study is considerable, and the resolution is insufficient for optimal characterization of coronary plaques. MRI capabilities may be enhanced with the use of agents to enhance contrast of macrophage presence.⁶² Novel agents have been developed for MR (and near-infrared [NIR]) molecular imaging that are activated by local enzymatic processes.⁶³ Strauss et al⁶⁴ have noted that the ability of nuclear studies to detect metabolic activity may eventually lead to successful noninvasive studies of vulnerable coronary artery plaques.

View larger version (168K): [in this window] [in a new window]   Figure 4. MRI of coronary plaque. A, Angiogram demonstrating high-grade left anterior descending artery (LAD) stenosis. B, Black-blood MRI image of LAD obtained in vivo shows the partially obstructed lumen. C, Wall image shows a large eccentric plaque with heterogeneous signal intensity possibly caused by the presence of lipid within the plaque (inset). Modified from Fayad et al61 with permission from the American Heart Association. Copyright 2000.

The development of methods to perform noninvasive characterization of coronary plaque will continue to be an active field of research that will be aided by results obtained by the invasive methods described below.

Invasive Imaging of Vulnerable Plaques in the Coronary Arteries
Invasive imaging methods have a great advantage over noninvasive methods in assessment of coronary plaques. Intracoronary catheters have an excellent vantage point close to the tissue of interest, and their movement is similar to that of their target. These advantages allow the invasive tools to provide more detailed information about coronary plaque composition, morphology, and extent than is possible with noninvasive approaches.

Numerous invasive approaches to characterize plaques are being evaluated. Coronary angiography can detect stenoses, but its limitations as a "lumenogram" have led to interest in imaging methods that provide information about the vessel wall.

Intravascular ultrasound (IVUS) can image the wall and thereby provide useful information on plaque volume and vessel remodeling. Novel IVUS methods have been developed to characterize the stiffness of plaques and to detect the presence of necrotic cores or fibrofatty tissue.⁶⁵

In addition to the acoustic techniques, optical methods can provide information about plaque characteristics. Angioscopy is the best method to detect intracoronary thrombus; it can also detect yellow plaque.⁶⁶ Optical methods that can penetrate beyond the surface of the plaque are also under development. Optical coherence tomography (OCT) can provide high-resolution views of cap thickness, plaque microarchitecture, and macrophage infiltration.⁶⁷ NIR spectroscopy is under development as a means to characterize the chemical composition of plaques.⁶⁸

Additional efforts include the development of a catheter-based MRI system that can identify lipid-rich tissue⁶⁹ and catheters to measure thermal gradients associated with inflammation in the coronary arteries.⁷⁰ Finally, molecular imaging agents may enhance identification of specific molecular processes within plaques.⁷¹

The most versatile of these techniques can function through blood and scan the artery rapidly; others require removal of blood and/or can interrogate only a specific location.

There are varying levels of evidence that each technique can precisely measure its feature of interest (plaque composition, cap thickness, etc) in vivo (Table 1). As this evidence is strengthened, a second more difficult question must be answered: Does the feature identified indicate that a given plaque is more likely to rupture and cause a coronary event? Although it is possible that angioscopic findings can predict coronary events,⁷² the natural history studies required to document predictive power for the novel techniques have only recently been initiated.

View this table: [in this window] [in a new window]   TABLE 1. Overview of the Invasive Methods for Plaque Characterization

Coronary Angiography
Although the coronary angiogram fails to identify most of the atherosclerotic changes affecting the vessel, it has provided some information about plaque vulnerability. Ambrose et al,⁷³ Little et al,⁷⁴ and others used the angiogram to demonstrate that, in most cases, vulnerable plaques do not produce a significant stenosis before they rupture and cause a coronary event.

In addition to identifying stenosis, the angiogram, particularly in patients with acute coronary syndromes, may reveal a complex, irregular interface between the luminal surface of the plaque and the injected contrast material^75,76 (Figure 5). Angioscopic and autopsy studies have documented that these complex lesions are caused by plaque rupture, intraplaque hemorrhage, and intraluminal thrombosis.^77,78

View larger version (38K): [in this window] [in a new window]   Figure 5. Complex angiographic morphology as a marker of high-risk lesions. The angiogram reveals a type II eccentric stenosis with a filling defect in the left anterior descending artery. The angioscopic image reveals a high-yellow color intensity plaque with intimal disruption and a mural thrombus, indicating that the "complex" angiographic appearance correctly identified a disrupted plaque with thrombus. Modified from Ishibashi et al66 with permission from Blackwell Publishing. Copyright 2006. Images courtesy of Drs Richard Nesto and Waxman.

Goldstein et al¹⁶ demonstrated that additional angiographically complex lesions may occur at sites other than the culprit in 40% of patients with acute MI. However, the number of additional lesions was not large and hence in accord with the autopsy studies demonstrating the single and sometimes oligofocal distribution of ruptured plaques and TCFAs described above.

Complex lesions have a moderately increased likelihood (20% to 40%) of causing progression of stenosis within the year after their discovery, presumably because of organization of the initial thrombus followed by repeat rupture.^79–83 Such lesions have also been linked to elevations in serum inflammatory markers and subsequent events.^16,84–86 The finding of multiple complex lesions in an angiogram may be a sign that the patient (as opposed to the individual plaque) is vulnerable because of an active systemic inflammatory process that will produce numerous vulnerable plaques in the future. Statin therapy, which can decrease signs of inflammation, may have decreased the linkage between complex lesions and subsequent events demonstrated in prior studies.⁸³

The coronary angiogram has also been used to identify patients with paradoxical coronary vasoconstriction, which has been linked to future cardiovascular events.^87–92 New angiographic systems permit the rapid display of 3D images that can serve as a scaffolding for display of findings of IVUS and other novel imaging methods.⁹³

IVUS-Based Methods
IVUS, which can be performed relatively easily and safely with a small catheter and does not require removal of blood, is used routinely in interventional cardiology and is being investigated as a means to identify vulnerable plaque.^94,95 The primary routine uses of IVUS are to identify the amount of stenosis in borderline lesions and to assist in stent deployment.⁹⁶ IVUS is also a valuable research tool for assessing the changes in plaque volume in response to novel antiatherosclerotic treatments.^97–100

Use of IVUS for Plaque Characterization and Assessment of Vulnerability
Standard IVUS is an excellent tool to determine whether plaques contain calcium, which produces a bright ultrasonic reflection. However, the association of calcification with plaque vulnerability is complex. Although calcification is associated with atherosclerosis, the plaques causing acute coronary syndromes have less calcium than those causing stable angina.¹⁰¹ Furthermore, stress analysis in autopsy specimens demonstrated that calcium does not increase fibrous cap stress and is less likely than a lipid pool to decrease mechanical stability of an atheroma.¹⁰² A spotty calcium pattern of calcification, which is more likely to be found in culprit lesions of patients with MI than in those of patients with stable angina, may be an indicator of vulnerability.^103,104

There have been efforts to use IVUS to identify other plaque components. Studies in autopsy specimens have shown that hypoechoic areas represent plaques with increased lipid content, low-intensity or "soft" echoes represent fibromuscular lesions, and moderately hyperechoic areas are associated with fibrous plaques.^105,106 A prospective study in a small number of patients found an increased risk of rupture and acute coronary syndrome caused by echolucent (presumably lipid-rich) plaques.¹⁰⁷ Despite these data, the subjective nature of IVUS interpretations and questions about the limited sensitivity and specificity in vivo of the gray-scale images^108,109 have led to attempts to improve the processing of the primary echo signal to enhance IVUS analysis of plaque composition.

These efforts have focused on novel methods to analyze the integrated backscatter of the radiofrequency (RF) signal to improve plaque characterization.^110–112 Nair et al¹¹² described an algorithm that could predict plaque composition of ex vivo human coronary plaques with an accuracy of 90%. A commercially available system has been developed (Volcano, Inc, Rancho Cordova, Calif) using this analysis that assigns plaque to the categories of fibrotic, fibrofatty, calcific, and necrotic core and has been termed "virtual histology" (Figure 6).

View larger version (33K): [in this window] [in a new window]   Figure 6. Plaque characterization by IVUS. A, A traditional gray-scale cross-sectional IVUS image showing a plaque in the left anterior descending artery. B, Corresponding image using Virtual Histology (Volcano, Inc) to present tissue characterization information based on spectral analysis of backscatter data. White indicates calcification; green, fibrotic tissue; greenish-yellow, fibrolipidic tissue; and red, necrotic core. Modified from Rodriguez-Granillo et al117 with permission from The American College of Cardiology Foundation. Copyright 2005.

A study by Kawasaki et al¹¹³ in patients with stable angina reported that 6 months of statin therapy causes changes in the RF IVUS signal consistent with a reduced lipid component indicating plaque stabilization. Fujii et al¹¹⁴ reported that positive (expansive) remodeling is more likely to occur in lesions that demonstrate fibrofatty plaque by IVUS. Sites with larger lipid cores by IVUS were more likely to be associated with expansive remodeling¹¹⁵ and to be located in the proximal portions of the coronary arteries.¹¹⁶ Patients with an acute coronary syndrome were more likely to have signs of a TCFA by virtual histology than were patients with stable angina.¹¹⁷

Follow-up data after RF imaging are becoming available. Sano et al¹¹⁸ compared the baseline IVUS findings in 10 patients in whom a coronary syndrome occurred during follow-up with the baseline findings in 143 patients in whom an event did not occur. Sites that led to an event were more likely to show an increased lipid area at baseline. The authors conclude that long-term, large-scale studies are needed to validate the approach. The Prospect Trial, which has already enrolled 700 patients, is an example of the type of study needed to determine whether IVUS signals can prospectively identify plaques and/or patients vulnerable to the occurrence of coronary events.

Detection of Ruptured Plaque by IVUS
IVUS can frequently identify ruptured plaques because they have a distinctive anatomic structure. The findings are similar to those of angiographic and autopsy studies. Ruptured plaques are observed more frequently in patients with MI¹¹⁹ than in patients with stable angina^120,121 and are associated with elevated hs-CRP.¹²² Patients with infarction are more likely to demonstrate >1 rupture site than are those with stable angina.¹²⁰ Ruptured plaques that caused an acute coronary syndrome are associated with a smaller lumen and a greater plaque burden than are plaques that ruptured without causing a clinical event.¹²³

Although a ruptured plaque was by definition "vulnerable" before its rupture, it is also suspected to remain "vulnerable" to subsequent episodes of rupture and thrombosis. Hence, detection of a ruptured plaque by IVUS might be considered to be detection of a certain type of vulnerable plaque. The issue is not resolved. One IVUS-based study has reported that ruptured plaques causing mild stenosis were not associated with subsequent stenosis progression or recurrent acute coronary syndromes after MI in patients receiving adequate medical therapy.¹²⁴ However, a second study demonstrated subsequent increases in stenosis at rupture sites in the absence of statin therapy.¹²⁵

The ability of IVUS to image deep into the wall of the artery has been used to evaluate remodeling in patients.¹²⁶ Culprit lesions in patients with acute coronary syndromes demonstrate more expansive remodeling by IVUS than do the culprit lesions of patients with stable angina, suggesting that expansive remodeling might be associated with plaque vulnerability.^127,128 Histological findings support this linkage because sites with expansive remodeling have larger lipid cores and more macrophages than sites with constrictive remodeling.¹²⁹ Hence, expansive remodeling, once thought to be beneficial because it reduced luminal narrowing, could be associated with a harmful predisposition to plaque rupture.^130,131

IVUS after injection of microbubbles can also be used to detect the vasa vasorum present in advanced plaques that might be an additional feature of vulnerable plaques.^132,133 Detection may be enhanced with the use of harmonic imaging after microbubble injection in which the signal is recorded at a higher frequency than that of the sonic waves directed to the plaque.¹³⁴

Elastography
IVUS can also be used to assess the deformation of plaques during the changes in intracoronary pressure that occur during the cardiac cycle.¹³⁵ This technique, called elastography, has been used to characterize the softness of plaques, which might be a sign of vulnerability.

Elastography has a high sensitivity and specificity for the detection of TCFAs in postmortem coronary artery specimens¹³⁶ (Figure 7). Deformable plaques are more frequent in patients with acute MI and unstable angina than in patients with stable angina and are associated with higher levels of hs-CRP.¹³⁷

View larger version (60K): [in this window] [in a new window]   Figure 7. Ex vivo images of a coronary TCFA obtained by IVUS (A) and elastography (B), followed by macrophage (C) and collagen staining (D). In the elastogram, a soft plaque is indicated by deformability (yellow, arrow) with higher pressure. Macrophage presence (C) is increased and collagen is decreased (D) over a lipid pool. Modified from Schaar et al136 with permission from the American Heart Association. Copyright 2003.

Studies performed in MI patients at baseline and after 6 months showed a decrease in the deformability of plaques, presumably resulting from institution of lipid-lowering therapy.¹³⁸ This promising technique is being tested in the Prospect Study and the Integrated Biomarker and Imaging Study (IBIS) 2 for its ability to predict coronary stenosis progression and events.

Profiling of Shear Stress by IVUS
IVUS has also been used to study shear stress produced by coronary artery blood flow, which may explain the localization of early plaque, TCFAs, and culprit lesions.^19,139,140 The technique uses 3D images of the vessel and computational fluid dynamics to calculate the force directed along the endothelial surface of the vessel wall resulting from the friction associated with blood flow (Figure 8).

View larger version (56K): [in this window] [in a new window]   Figure 8. Map of endothelial shear stress in the coronary artery created by data from IVUS, biplane cineangiography, and computational fluid dynamics. Low shear stress (blue areas) may lead to positive remodeling and the formation of TCFA. Image courtesy of Dr Peter H. Stone.

Plaque is more likely to originate at sites that have lower shear stress, which predisposes to inflammation and endothelial dysfunction.¹⁴¹ With such dysfunction, monocytes and lipids are more likely to penetrate the vessel wall, leading to TCFA formation, expansive remodeling, stenosis progression, and vulnerability.¹⁴² Hence, measurement of shear stress might be a method to identify sites that are "vulnerable" to becoming vulnerable. Detection of early steps in the process would be of considerable value, particularly if the time course of the appearance of vulnerable plaques, which is currently unknown, is relatively rapid.

Optical Methods to Detect Vulnerable Plaque
Angioscopic Examination of the Coronary Artery
Coronary angioscopy is currently the most precise clinical method available to identify the presence of thrombus, plaque disruption, and variations in color of the coronary arterial wall (Figure 9). During angioscopic examination, disruption appears as an irregular area, and thrombus is seen as a red, pink, or whitish mass. Nondisrupted plaques may be white, indicating a fibrotic composition, or yellow as a result of lipids that are rich in carotenoid pigments.^143,144 The intensity of the yellow correlates inversely with cap thickness; a glistening yellow color indicates that a TCFA is present.^72,145

View larger version (59K): [in this window] [in a new window]   Figure 9. A, Angioscopic image of a yellow plaque obtained in a human coronary autopsy specimen. B, Histology reveals that a TCFA is present. Image courtesy of Drs Ishibashi and Waxman.

Despite its capabilities, angioscopy is rarely used in clinical practice because it requires a blood-free field of view. The technique is valuable for research, with most use occurring in Japan.^146,147

Angioscopic Findings in Patients With Stable Angina the Acute Coronary Syndromes
Angioscopic signs of both thrombus and disruption of the culprit site are more frequent in patients with unstable angina and MI than in patients with stable angina.^148–150 Angioscopy has also confirmed the presence of disrupted and thrombotic plaques at sites other than the culprit lesion.^151,152

Because ruptured plaques with thrombi may be prone to recurrent thrombosis,¹⁵³ it is possible that these ruptured plaques detected by angioscopy may be a type of vulnerable plaque. Nonculprit lesions with disruption or thrombus detected by angioscopy tend to heal but may cause progression of angiographic stenosis.¹⁵² Healing was more likely to occur in patients with lower hs-CRP levels and more intensive statin therapy than in other patients.

Angioscopic Assessment of Yellow Color
Yellow plaques, which may be associated with vulnerability, are 5 times more likely to be associated with thrombus than are white plaques,¹⁵⁴ and the culprit lesions in patients with MI are often yellow.¹⁵⁵ Because visual assessment of yellow is subjective and affected by multiple variables, efforts are being made to develop quantitative colorimetry systems.^145,156,157

Not all sites that are yellow by angioscopy are associated with acute coronary syndromes. Yellow plaque frequently occurs at nonculprit sites in patients with acute MI,¹⁵⁸ and yellow plaques not associated with thrombosis occur in 50% to 60% of patients with stable angina.¹⁵¹ Although these findings indicate the diffuse nature of atherosclerosis, it remains possible that the more locally occurring TCFAs, which are a subset of yellow plaques, might represent focal sites of vulnerability.

Uchida et al⁷² conducted one of the first reported studies of the natural history of lesions suspected to be vulnerable. Angioscopy was performed in 157 patients with stable angina. Over the subsequent 12 months, 68% of those with glistening yellow plaque experienced a coronary event as opposed to 8% in those with nonglistening yellow plaque and 3% in those with white plaques only. This important finding, which could represent the prospective identification of vulnerable plaque, requires replication in a larger study.

Angioscopy can also be used to assess the effect of preventive treatment.¹⁵⁹ Therapy with atorvastatin changed lesions from yellow to white, suggesting plaque stabilization.¹⁶⁰

Intravascular OCT
OCT uses the back-reflection of NIR light from optical interfaces in tissue to create high-resolution (10 µm), cross-sectional images.¹⁶¹ It provides a clearer picture of plaque structures than IVUS, which has a resolution of 100 µm.¹⁶² Autopsy studies have documented that OCT can accurately identify fibrous, fibrocalcific, lipid-rich plaques and macrophages and is the best technique to measure cap thickness^163,164 (Figure 10).

View larger version (38K): [in this window] [in a new window]   Figure 10. OCT image of ruptured TCFA in a patient with acute MI (A). A lipid pool (L), intimal disruption (arrow), and guidewire artifact (asterisk) are visible. Macrophage density data are superimposed on the image (B). Modified from Tearney et al161 with permission from the International Society for Optical Engineering. Copyright 2006.

The main limitation of intravascular OCT is the attenuation of the signal because of blood. Systems have been designed to remove blood from the field of view.¹⁶⁵ These requirements limit the time for imaging and increase the complexity of use. A modification of OCT, called optical frequency domain imaging, is under development. It will permit much more rapid acquisition of the signal and may allow scanning of a considerable portion of the artery during a single flush.¹⁶⁶

The promising features of OCT documented ex vivo can be obtained in the clinical setting. In 57 patients undergoing PCI, the OCT signs of lipid-rich plaques were observed in 90% of MI patients, 75% of acute coronary syndrome patients, and 59% of stable angina patients. The frequency of fibrous cap 65 µm was 72%, 50%, and 20% in the MI, acute coronary syndrome, and stable patients, respectively.¹⁶⁷ The OCT sign of macrophage presence was higher in patients with acute coronary syndromes than in patients with stable angina.¹⁶⁸ Pilot studies are underway to determine whether OCT can predict the progression of coronary stenosis.

Intracoronary NIR Spectroscopy
Diffuse reflectance NIR spectroscopy is in widespread use in many fields to identify the chemical composition of unknown substances.¹⁶⁹ Because it appeared to be well suited for the identification of the composition of atherosclerotic plaques, several investigators tested its ability to identify lipids in ex vivo studies of autopsy or endarterectomy specimens.^170–172 TCFAs and ruptured plaques could be readily identified by spectroscopy, even in the presence of up to 2 mm blood.¹⁷³ There was doubt, however, as to whether NIR spectroscopy could be performed within the coronary arteries of patients in whom problems of cardiac motion, blood flow, and the need to scan entire arteries must be overcome.

A catheter-based NIR spectroscopy device has now been constructed and successfully tested in 16 patients with stable angina and 10 with acute coronary syndromes. The device, which is similar in size and use to an IVUS catheter, was well tolerated and provided a full scan of the area of interest. High-quality spectra were obtained that are similar to those obtained in autopsy studies (Figure 11). Signals obtained from the wall of the coronary artery in vivo differed from those obtained from blood alone.

View larger version (43K): [in this window] [in a new window]   Figure 11. NIR spectroscopic findings in the left anterior descending artery of a patient with stable angina pectoris. Top, Spectral shape contained in the data that is associated with lipid. Bottom, Amount of that shape present at each pixel as the catheter was pulled back (x axis) and rotated (y axis) within the coronary artery. The white areas indicate the location of the guidewire. Although the algorithm is not yet validated, the display shows the ability of the NIR system to obtain relevant signals in patients. Modified from Caplan et al173 with permission from The American College of Cardiology Foundation. Copyright 2006.

NIR studies have also been performed in a hypercholesterolemic swine model with extensive lipid-rich plaques.¹⁷⁴ In this in vivo study in which coronary motion and blood flow were present, there was excellent reproducibility of NIR signals on repeat pullbacks and with different catheters (InfraReDx data on file).

Studies are underway in intact, perfused human coronary artery autopsy specimens to compare the NIR signals obtained with the scanning system with the gold standard of histology and create an advanced algorithm that will be used to interpret NIR signals obtained in patients. A registry has been established to determine the relationship of NIR findings to coronary events, as discussed below.

Raman NIR spectroscopy has also been studied for the assessment of coronary plaque composition.^175–177 Raman differs from diffuse reflectance NIR spectroscopy in that it is based on the shift of photons to a different wavelength by the tissue being imaged. The Raman shift is more specific for individual chemicals than is diffuse NIR reflectance, but the signal is much weaker and therefore more difficult to detect in vivo. Raman spectroscopy has been shown to be capable of differentiating atherosclerotic plaque from diffuse intimal thickening ex vivo in carotid endarterectomy specimens.¹⁷⁸

A compact fiberoptic-based Raman system for in vivo applications has been developed.¹⁷⁹ In autopsy studies of human coronary arteries and aortas, the system detected cholesterol and calcification in specimens. This performance indicates that Raman spectroscopy has the potential to perform plaque characterization in patients if problems of in vivo measurement can be overcome.

Thermography
In 1996, Casscells et al⁷⁰ studied the temperature of human atherosclerotic plaques in an ex vivo setting after a carotid endarterectomy. Inflamed plaques with increased macrophage density had a higher temperature than plaques that were not inflamed.¹⁸⁰ These positive findings led to efforts by several groups to measure the temperature of plaques in patients undergoing catheterization.^181,182

It has been learned that coronary blood flow and catheter design features complicate measurement of plaque temperature in vivo.¹⁸³ Blood flow is a coolant for the heart, which generates heat as a result of its contraction.¹⁸⁴ This cooling effect makes it difficult to measure relatively small increases in plaque temperature without interrupting blood flow. In addition, catheters with increased sensitivity are needed to measure the relatively small thermal signal. Prospective studies are planned to assess the feasibility of intracoronary temperature measurement and then test the ability of a temperature elevation to predict cardiac events.

Intravascular MRI
As noted, the noninvasive use of MRI to identify lipid in coronary plaques is limited by the small size of the target and cardiac motion. Two invasive MRI approaches are under development to overcome these problems. In the first, the patient is placed in a standard external MRI magnet, and an intravascular RF coil is used for local measurement. In the second, all the components required for the MRI measurement—magnets, RF coil, and detectors—are located in a single coronary catheter.⁶⁹

Studies using the first approach in vivo in human iliac arteries obtained results similar to those of IVUS in the assessment of plaque size and signs of lipid.¹⁸⁵ The method can also quantify components of atherosclerosis in human aortic autopsy specimens¹⁸⁶ and in carotid endarterectomy specimens.¹⁸⁷ The feasibility of accurate in vivo imaging has been demonstrated in rabbits and swine.^188,189 This approach has the disadvantage of requiring that a patient must be studied in a suite containing an MRI magnet.

The second approach, in which the entire system is located on a catheter, has been validated ex vivo in aortic and coronary tissue (Figure 12). This approach showed significant differences in apparent diffusion coefficients between fibrous tissue, fatty streak, and lipid-rich necrotic cores.¹⁹⁰ Data have now been collected in 61 coronary patients.¹⁹¹

View larger version (33K): [in this window] [in a new window]   Figure 12. A self-contained intravascular MRI system with imaging areas superimposed on a human coronary artery (left). The arrowhead depicts 1 of 4 fields of view. The diagram (right) displays the lipid fraction in each quadrant in an ex vivo autopsy specimen. An increased lipid concentration is displayed in yellow. Reproduced from Schneiderman et al190 with permission from The American College of Cardiology Foundation. Copyright 2005.

	Potential Treatment of Vulnerable Plaques

Top Introduction Vulnerable Plaque Methods to Image Vulnerable... Potential Treatment of... Conclusions References

 
It is likely that many agents already proven to prevent coronary events achieve their effect by reducing plaque vulnerability. Studies in animals have demonstrated that lipid-lowering diets and treatments convert fatty, presumably vulnerable plaques into fibrotic, presumably less vulnerable forms.¹⁹² Studies in patients in which the ability of lipid-lowering therapy to prevent events was far greater than its measurable effect on the degree of stenosis support such a concept.¹⁹³

Although plaque stabilizing therapies are a welcome addition, many events continue to occur in patients receiving the best currently available therapy. In the Prove-It Trial, 22.4% of patients experienced a coronary event during 2 years of intensive statin therapy.³⁵

The best long-term approach to prevention of coronary events is lifestyle changes supplemented by a fully effective systemic therapy, but such a regimen is not yet available. In addition, some patients will present with advanced disease, and others will not comply with such a regimen. Hence, it may be useful to supplement systemic therapy with effective local therapy for the most advanced lesions. Such an approach would be similar to the treatment of breast cancer with systemic chemotherapy plus local radiation.

Systemic Therapy
A number of newer systemic pharmacological approaches to coronary prevention are related to plaque vulnerability.

Therapies to Lower LDL Cholesterol
There is no doubt that intense lowering of LDL, which can be readily achieved by statin therapy, can prevent events resulting from complications from vulnerable plaques.¹⁹⁴ Although direct evidence that such beneficial effects are due to plaque stabilization is not available, various imaging methods have been used to determine the effect of statins and other therapies on coronary and carotid artery plaques.

Nissen et al⁹⁸ studied the effect of intensive lipid lowering with rosuvastatin on coronary atheroma in 507 patients undergoing IVUS examination at baseline and after 2 years of follow-up. The marked reduction in LDL was associated with an 11.1% decrease in coronary plaque volume as measured by IVUS. Although the study was not randomized and HDL increases also occurred, it is quite likely that the intense LDL lowering produced this beneficial decrease in plaque volume and stabilized plaques.

The effect of lipid lowering on calcification is complex. Noninvasive studies have shown that plaque calcification can actually increase during statin therapy.^195,196

The beneficial effects of statin therapy observed in the coronary circulation have also been observed in the carotid arteries and the aorta. Corti et al¹⁹⁷ used noninvasive MRI measurement to document that statins caused regression of atherosclerotic carotid and aortic lesions in patients.

Animal studies have provided information about the mechanisms of plaque stabilization by statin therapy. A study of rabbits transferred from an atherogenic to a regression diet revealed that collagen content of the plaques increased.¹⁹² It has also been demonstrated in rabbits that statin therapy reduced macrophages and collagen breakdown products in lipid pools.¹⁹⁸

Therapies to Increase HDL Cholesterol
It is likely that increases in HDL would increase plaque stability because such changes accelerate reverse cholesterol transport, lowers oxidation level, and decreases inflammation. Clinical studies have documented the prevention of coronary events with HDL raising by niacin and gemfibrozil therapy.^199,200 A major National Institutes of Health study has been initiated to determine whether significant increases in HDL levels induced by niacin therapy can reduce coronary events.

Inhibitors of cholesteryl ester transport protein have emerged as promising agents to increase HDL levels. Torcetrapib and JTT-705 can produce elevations of 50% in HDL cholesterol.^201,202 Clinical trials are in progress to determine whether such HDL elevations produce the expected clinical benefits.²⁰³

The atheroprotective effects of apoA-1 Milano, a synthetic form of HDL, have received considerable attention.^204,205 The agent was infused weekly for 5 weeks into patients recovering from an acute coronary syndrome. IVUS measurements demonstrated a small decrease in atheroma volume, supporting the transition to studies with clinical end points.²⁰⁶

Additional approaches in this active field include the use of small molecules to increase HDL levels and a variety of nuclear hormone receptor agonists to increase ABC gene transcription and HDL levels and/or function. There are also efforts to evaluate systemic administration of unilamellar phospholipid vesicles and gene therapy involving HDL-related proteins.²⁰⁷

Antiinflammatory Therapy for the Prevention of Coronary Events
The evidence that atherosclerosis is associated with inflammation has increased interest in the role of antiinflammatory agents in preventing coronary events.^22,208 The concept is supported by the success of statin therapy, which may be due in part to antiinflammatory effects.^35,36

Lipoprotein-associated phospholipase A2 has emerged as a promising novel target for antiinflammatory therapy of atherosclerosis.³⁸ This lipase circulates in plasma and can enter the vessel wall. Once in the wall, it interacts with macrophages and lymphocytes to intensify local inflammatory processes. A small-molecule inhibitor of lipoprotein-associated phospholipase A₂ is under study.²⁰⁹

An agent that can block endothelial cell signaling pathways that facilitate the movement of monocytes into the vessel wall is being studied. AGI-1067 blocks the production of vascular cell adhesion molecule 1 and has antioxidant and lipid-lowering activity.²¹⁰ It has been shown to reduce restenosis after PCI and to increase the luminal dimensions of reference segments.²¹¹ A randomized study is underway in 6000 patients to determine whether AGI-1067 can reduce coronary events.

Summary of Systemic Therapy for Vulnerable Plaque
Ambrose and D’Agate²¹² have proposed a useful classification to assess the likelihood that a given systemic therapy is plaque stabilizing (Table 2). Therapies are grouped by the strength of the evidence that they prevent coronary events and the plausibility of a mechanism by which they might do so by stabilizing vulnerable plaques.

View this table: [in this window] [in a new window]   TABLE 2. Classification of Systemic Therapy for Vulnerable Plaque

Although systemic therapy is clearly the preferred solution, current systemic therapy does not provide adequate protection, particularly for the very-high-risk group of patients whose disease activity has led to the need for a PCI. This situation leads to the following question: At the present time, is there a role for local preventive therapy as a supplement to systemic therapy in a patient already undergoing PCI?

Local Therapy for Vulnerable Plaque
The sine qua non of local therapy for vulnerable plaque is the existence and prospective detection of local areas of the vessel that are at increased risk of causing a coronary event. If the entire artery is found to be at high risk or if vulnerability rapidly emerges and resolves, there may be no role for local therapy. However, local diagnosis might still be of value as a guide to the intensity of systemic therapy, as is the case for cancer in which results of a local biopsy often guide systemic therapy.

In the context of uncertainty about the existence, detection, and timing of plaque vulnerability, it is not possible to recommend routine use of the promising local therapy options discussed below. Such therapy can be recommended only with the use of a vulnerability detector and the availability of data from a randomized trial demonstrating that the local therapy under consideration provides benefits greater than the complications associated with the intervention.

Evaluation of the promising local treatments for vulnerable plaque (stents, photodynamic therapy, and other options) is therefore being hindered by the absence of validated diagnostic devices. For the vulnerable plaque hypothesis, detection of risk appears to be a more formidable obstacle than availability of possible treatments.

Treatment of Coronary Artery Risk Based on Location of Culprit Lesions
Although technologies to identify risk caused by an individual plaque are not yet validated, Wang et al¹⁸ have identified regions of risk in arteries based on location of culprit lesions. It was found that most of the lesions causing the acute coronary syndromes occur within the proximal 30 mm of the major coronary arteries. These are also areas of decreased shear stress and increased numbers of TCFAs and ruptured plaques.¹⁷

Because the risk is associated with a relatively limited length of artery, it is possible that regional therapy (possibly with stents) might be useful for preventing subsequent events in patients undergoing PCI. Wang and colleagues¹⁸ have suggested that a randomized trial of such an approach might be conducted in high-risk patients. The trial might also use a vulnerability detector to identify patients with vulnerable arteries who would be the most likely to derive benefit.

Stents for the Treatment of Vulnerable Coronary Plaques and Arteries
Drug-eluting stents have been evaluated in an atherosclerotic rabbit model as a possible treatment for vulnerable plaques. Placement of a stent over lesions in the aorta reduced lipid core size and induced formation of an additional fibrous cap over the lipid pool (Figure 13). Although these results are encouraging, the benefits of stenting vulnerable plaques in patients must be shown in a randomized trial to exceed the complications, which include periprocedural infarction, restenosis, and stent thrombosis.²¹³

View larger version (67K): [in this window] [in a new window]   Figure 13. The results of placing a stent over a TCFA in the aorta of a 4-year-old cholesterol-fed rabbit. Stenting induced formation of an additional fibrous cap over the original lipid pool (yellow arrow). Image courtesy of Dr Pedro Moreno.

Stenting for Intermediate Coronary Artery Stenoses That Are Not Flow Limiting
There is generally little difficulty with the decision to stent a culprit lesion. It is causing or has caused ischemia, and the need for the stent is relatively straightforward and indicated by guidelines.²¹⁴ Unfortunately, many patients also have a second or third stenosis that is not producing ischemia but causes concern because it is suspected to be vulnerable. The concern is heightened if the lesion causes a 50% to 60% diameter stenosis, has a complex angiographic appearance, and is in a precarious location such as the proximal left anterior descending coronary artery.

In the absence of information about the likelihood that the plaque of concern might rupture, current guidelines call for the use of medical therapy. However, if the lesion were known to be vulnerable to rupture, stenting might be the better choice, depending on the balance of risks and benefits of stenting noted above.²¹⁵

The use of stents or angioplasty for lesions causing an intermediate stenosis was examined in the Defer Trial. Patients with intermediate stenoses not causing a significant reduction in fractional flow reserve were randomly assigned to intervention (angioplasty or stenting) or medical therapy. In a 5-year follow-up, there was no difference in the low rate of cardiac death and MI between patients assigned to medical therapy and those treated with the intervention.²¹⁶ It was concluded that the low risk of MI and cardiac death in this population (<1% per year) did not justify intervention for intermediate stenoses in this group of patients. However, the study excluded patients with more active disease who had sustained an MI or unstable angina and did not use a vulnerability detector. The possibility that stenting of intermediate lesions suspected to be vulnerable will be of value in acute coronary syndrome patients has led to a proposal to conduct the Prevail Trial, a randomized trial of the strategy.

Improvements in stent technology are likely to reduce the risks associated with stenting and thereby shift the risk-to-benefit ratio toward the stenting of intermediate stenosis. Bioabsorbable stents, which may reduce or eliminate the long-term risk of stent thrombosis, may be preferable for prophylactic stenting of nonstenotic vulnerable plaques.

Role of Vulnerability Detection in the Selection of Stenting Versus CABG as Optimal Therapy
In several commonly encountered clinical situations, knowledge of the vulnerability of the artery in question might be useful as a guide to treatment with stents or referral for surgery. For diabetics with stenosis in 3 vessels, the current standard of care is CABG because of documented reductions in cardiac events with surgery that are not achieved by multivessel stenting.²¹⁷ The bypass graft, which is attached distal to much of the epicardial coronary artery, presumably bypasses nonstenotic vulnerable plaques that would otherwise be responsible for subsequent events. Stenting of flow-limiting lesions, which is a focal treatment, would not provide such a benefit.

However, if it were possible to determine whether the arteries contained vulnerable nonstenotic plaques, the triage of such patients to stenting or CABG could be improved. Patients with stenoses and no evidence of nonstenotic vulnerable plaques could be treated with stenting, and those with extensive signs of vulnerability could be sent for CABG.

Multiple trials are in progress to compare the value of multivessel stenting with surgical treatment of patients with stenosis in 3 coronary vessels. Such trials would be aided by the detection of vulnerability and assessment of the degree of stenosis.

Similar considerations apply to therapy for patients with isolated left main coronary artery stenosis. If a localized left main stenosis is present and the remainder of the arteries show no evidence of significant stenosis or vulnerability, stenting might be the preferred therapy. Alternatively, if there were signs of diffuse vulnerability throughout the artery, CABG might be preferred.

PTCA for the Treatment of Vulnerable Coronary Plaques
In 1995, Meier²¹⁸ proposed that it might be of value to intentionally rupture presumably vulnerable intermediate stenoses with balloon angioplasty at the time of catheterization. Because the rupture would occur under controlled conditions and in the presence of intensive antithrombotic therapy, the procedure would not cause an acute coronary event. After the catheterization, the ruptured lipid-rich plaque would be expected to become a fibrotic plaque, and the danger of a coronary event would be eliminated. The procedure was called plaque sealing.²¹⁹ The concept stimulated extensive debate but did not become an accepted practice.

Plaque sealing, however, could be reconsidered in light of new technical developments. The availability of stents provides an excellent treatment for the problems of subacute occlusion that limited the value of PTCA for preventive purposes. In addition, it is possible that a vulnerability detector might be able to identify the lesions most in need of therapy. The use of PTCA to intentionally rupture nonstenotic vulnerable plaques would not carry the long-term risks of stenting. Plaque sealing and all local therapies under discussion require evaluation in randomized trials.

Photodynamic Therapy for Vulnerable Coronary Arteries and Plaques
Photodynamic therapy has been proposed as a method to stabilize a specific plaque or a region of an artery by selective ablation of macrophages or other targeted cells.²²⁰ The photosensitizing agent motexafin lutetium was tested in atherosclerotic rabbits. After photoactivation via an intra-aortic catheter, there was a marked reduction in the number of macrophages and a small decrease in atheroma burden without damage to normal tissue²²¹ (Figure 14). The same agent has been administered to patients undergoing coronary stenting in a safety study and found to be well tolerated.²²²

View larger version (49K): [in this window] [in a new window]   Figure 14. Photodynamic therapy to reduce inflammation and possibly stabilize plaques. Cross-sectional segments of iliac arteries in a cholesterol-fed and balloon-injured rabbit model obtained 2 weeks after treatment with motexafin lutetium, a photosensitizing agent, and in vivo photoactivation. The treated lesion (a) shows almost complete eradication of macrophages (brown by RAM-11 stain) in the intima, whereas in the nontreated lesion (b), macrophages are present throughout the vessel. Modified from Hayase et al221 with permission from the European Society of Cardiology. Copyright 2001.

Using a different photodynamic agent, Waksman et al²²³ demonstrated that photodynamic therapy can reduce neointimal growth without suppressing reendothelialization of a stent in a porcine model. These early results suggest that photodynamic therapy might eventually have a role in the local or regional treatment of vulnerability.

Cooling, Heating, and Sonotherapy
Cryoenergy has been shown to reduce restenosis and increase the density of type III collagen in balloon-injured porcine arteries.²²⁴ It may be useful to stabilize vulnerable plaques because it can induce local apoptosis without causing excessive neointimal proliferation. Cryoenergy is currently being studied for the treatment of peripheral arterial disease.²²⁵ Although heating and sonotherapy have also been considered as possible methods to treat vulnerable plaque,⁷⁰ little supporting evidence is available.²²⁶

	Conclusions

Top Introduction Vulnerable Plaque Methods to Image Vulnerable... Potential Treatment of... Conclusions References

 
The extensive activity described here has great promise to enhance the detection and treatment of vulnerability and thereby prevent coronary events. The net result of improved risk stratification will be better assessment of the risk/benefit relationships for the novel therapies that are needed. This balance will require increased attention because novel antiatherosclerotic agents and treatments are likely to be costly and may carry unanticipated side effects.

As indicated in Table 3, many of the trials required to test the hypothesis that diagnosis and therapy of vulnerability are possible and beneficial are planned or in progress. In aggregate, the planned trials account for >6000 patients.

View this table: [in this window] [in a new window]   TABLE 3. Summary of Prospective Clinical Trials (in Progress or Planned) to Determine the Outcome Associated With Plaques Characterized by Intracoronary Diagnostic Devices

Although the efforts required to test the vulnerability hypothesis are considerable, they are justified by the benefits that could be achieved. Effective screening and treatment in the general population would decrease sudden death and initial MI, and success in the catheterization laboratory would decrease the high risk of recurrence that now follows PCI. Because the costly disorders of heart failure and arrhythmia would be prevented, economic analysis indicates that treatment of vulnerability would actually lower healthcare costs while decreasing morbidity and mortality resulting from coronary artery disease.²²⁷

	Acknowledgments

 
Source of Funding

Dr Waxman has received a grant from InfraReDx, Inc. to conduct clinical trials of a spectroscopy catheter.

Disclosure

Dr Muller is on leave of absence from his academic positions and is currently chief executive officer of InfraReDx, Inc, a company developing an NIR catheter. The other authors report no disclosures.

	References

Top Introduction Vulnerable Plaque Methods to Image Vulnerable... Potential Treatment of... Conclusions References

 
1. Cardiovascular Disease Statistics. Available at: www.americanheart.org.

2. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004; 110: 1226–1230.[Abstract/Free Full Text]

3. Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation. 2005; 111: 143–149.[Abstract/Free Full Text]

4. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994; 23: 809–813.[Abstract]

5. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657–671.[Free Full Text]

6. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000; 20: 1262–1275.[Free Full Text]

7. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003; 108: 1664–1672.[Abstract/Free Full Text]

8. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol. 2002; 15: 439–446.[Medline] [Order article via Infotrieve]

9. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, Colombo A, Stefanadis C, Ward Casscells S, Moreno PR, Maseri A, van der Steen AF. Terminology for high-risk and vulnerable coronary artery plaques: report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J. 2004; 25: 1077–1082.[Abstract/Free Full Text]

10. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque, part I: evolving concepts. J Am Coll Cardiol. 2005; 20: 46: 937–954.

11. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, Virmani R. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996; 93: 1354–1363.[Abstract/Free Full Text]

12. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation. 2003; 107: 2068–2071.[Free Full Text]

13. Lutgens E, van Suylen RJ, Faber BC, Gijbels MJ, Eurlings PM, Bijnens AP, Cleutjens KB, Heeneman S, Daemen MJ. Atherosclerotic plaque rupture: local or systemic process? Arterioscler Thromb Vasc Biol. 2003; 23: 2123–2130.[Abstract/Free Full Text]

14. Shin J, Edelberg JE, Hong MK. Vulnerable atherosclerotic plaque: clinical implications. Curr Vasc Pharmacol. 2003; 1: 183–204.[CrossRef][Medline] [Order article via Infotrieve]

15. Libby P. Act local, act global: inflammation and the multiplicity of "vulnerable" coronary plaques. J Am Coll Cardiol. 2005; 45: 1600–1602.[Free Full Text]

16. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O’Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000; 343: 915–922.[Abstract/Free Full Text]

17. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, Finn AV, Virmani R. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001; 16: 285–292.[CrossRef][Medline] [Order article via Infotrieve]

18. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004; 20: 110: 278–284.

19. Stone PH, Coskun AU, Yeghiazarians Y, Kinlay S, Popma JJ, Kuntz RE, Feldman CL. Prediction of sites of coronary atherosclerosis progression: in vivo profiling of endothelial shear stress, lumen, and outer vessel wall characteristics to predict vascular behavior. Curr Opin Cardiol. 2003; 18: 458–470.[CrossRef][Medline] [Order article via Infotrieve]

20. Slager CJ, Wentzel JJ, Gijsen FJ, Schuurbiers JC, van der Wal AC, van der Steen AF, Serruys PW. The role of shear stress in the generation of rupture-prone vulnerable plaques. Nat Clin Pract Cardiovasc Med. 2005; 2: 401–407.[CrossRef][Medline] [Order article via Infotrieve]

21. Daugherty A, Webb NR, Rateri DL, King VL. Thematic review series: the immune system and atherogenesis: cytokine regulation of macrophage functions in atherogenesis. J Lipid Res. 2005; 46: 1812–1822.[Abstract/Free Full Text]

22. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135–1143.[Abstract/Free Full Text]

23. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685–1695.[Free Full Text]

24. Duff GW, Libby P, Ordovas JM, Reilly PR The future of living well to 100. Am J Clin Nutr. 2006; 83: 488S–490S.[Free Full Text]

25. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005; 111: 3481–3488.[Abstract/Free Full Text]

26. Mazzolai L, Duchosal MA, Korber M, Bouzourene K, Aubert JF, Hao H, Vallet V, Brunner HR, Nussberger J, Gabbiani G, Hayoz D. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE^–/– mice. Hypertension. 2004; 44: 277–282.[Abstract/Free Full Text]

27. Eriksson EE. Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol. 2004; 15: 553–558.[CrossRef][Medline] [Order article via Infotrieve]

28. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, Smialek J, Virmani R. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol. 2000; 157: 1259–1268.[Abstract/Free Full Text]

29. Zadelaar AS, von der Thusen JH, Boesten LS, Hoeben RC, Kockx MM, Versnel MA, van Berkel TJ, Havekes LM, Biessen EA, van Vlijmen BJ. Increased vulnerability of pre-existing atherosclerosis in ApoE-deficient mice following adenovirus-mediated Fas ligand gene transfer. Atherosclerosis. 2005; 183: 244–250.[CrossRef][Medline] [Order article via Infotrieve]

30. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol. 2005; 45: 1018–1024.[Abstract/Free Full Text]

31. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, de Vries JP, Verheijen J, Hanemaaijer R, de Kleijn DP, Pasterkamp G. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimens pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006; 37: 235–239.[Abstract/Free Full Text]

32. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, Badimon JJ, O’Connor WN. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004; 110: 2032–2038.[Abstract/Free Full Text]

33. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003; 349: 2316–2325.[Abstract/Free Full Text]

34. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004; 109 (suppl): II-2–II-10.[Medline] [Order article via Infotrieve]

35. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 20–28.[Abstract/Free Full Text]

36. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O’Shaughnessy C, Ganz P, for the Reversal of Atherosclerosis With Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005; 352: 29–38.[Abstract/Free Full Text]

37. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER): can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006; 97: 33A–41A.[CrossRef][Medline] [Order article via Infotrieve]

38. Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease: West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000; 343: 1148–1155.[Abstract/Free Full Text]

39. Li JJ, Fang CH, Chen MZ, Chen X, Lee SW. Activation of nuclear factor-kappaB and correlation with elevated plasma c-reactive protein in patients with unstable angina. Heart Lung Circ. 2004; 13: 173–178.[CrossRef][Medline] [Order article via Infotrieve]

40. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354: 1264–1272.[Abstract/Free Full Text]

41. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque, part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol. 2005; 46: 1209–1218.[Abstract/Free Full Text]

42. Chen JW, Wasserman BA. Vulnerable plaque imaging. Neuroimaging Clin N Am. 2005; 15: 609–621, xi.[CrossRef]

43. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke. 2005; 36: 2764–2772.[Abstract/Free Full Text]

44. Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the Tromso study. Circulation. 2001; 103: 2171–2175.[Abstract/Free Full Text]

45. O’Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol. 2002; 90: 18L–21L.[CrossRef][Medline] [Order article via Infotrieve]

46. Mitsumori LM, Hatsukami TS, Ferguson MS, Kerwin WS, Cai J, Yuan C. In vivo accuracy of multisequence MR imaging for identifying unstable fibrous caps in advanced human carotid plaques. J Magn Reson Imaging. 2003; 17: 410–420.[CrossRef][Medline] [Order article via Infotrieve]

47. Cappendijk VC, Cleutjens KB, Kessels AG, Heeneman S, Schurink GW, Welten RJ, Mess WH, Daemen MJ, van Engelshoven JM, Kooi ME. Assessment of human atherosclerotic carotid plaque components with multisequence MR imaging: initial experience. Radiology. 2005; 234: 487–492.[Abstract/Free Full Text]

48. Trivedi RA, U-King-Im JM, Graves MJ, Horsley J, Goddard M, Kirkpatrick PJ, Gillard JH. MRI-derived measurements of fibrous-cap and lipid-core thickness: the potential for identifying vulnerable carotid plaques in vivo. Neuroradiology. 2004; 46: 738–743.[CrossRef][Medline] [Order article via Infotrieve]

49. Li ZY, Howarth S, Trivedi RA, U-King-Im JM, Graves MJ, Brown A, Wang L, Gillard JH. Stress analysis of carotid plaque rupture based on in vivo high resolution MRI. J Biomech. October 26, 2005. DOI: 10.1016/j.biomech.2005.08.022. Available at: http://www.sciencedirect.com. Accessed September 19, 2006.

50. Ruberg FL, Viereck J, Phinikaridou A, Qiao Y, Loscalzo J, Hamilton JA. Identification of cholesteryl esters in human carotid atherosclerosis by ex vivo image-guided proton MRS. J Lipid Res. 2006; 47: 310–317.[Abstract/Free Full Text]

51. Davies JR, Rudd JH, Fryer TD, Graves MJ, Clark JC, Kirkpatrick PJ, Gillard JH, Warburton EA, Weissberg PL. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005; 36: 2642–2647.[Abstract/Free Full Text]

52. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, Lamuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. In vivo FDG-PET imaging provides a non-invasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. In press.

53. Nieman K, van der Lugt A, Pattynama PM, de Feyter PJ. Noninvasive visualization of atherosclerotic plaque with electron beam and multislice spiral computed tomography. J Interv Cardiol. 2003; 16: 123–128.[Medline] [Order article via Infotrieve]

54. Achenbach S. Current and future status on cardiac computed tomography imaging for diagnosis and risk stratification. J Nucl Cardiol. 2005; 12: 703–713.[CrossRef][Medline] [Order article via Infotrieve]

55. Achenbach S, Daniel WG. Computed tomography of the coronary arteries: more than meets the (angiographic) eye. J Am Coll Cardiol. 2005; 46: 155–157.[Free Full Text]

56. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004; 291: 210–215.[Abstract/Free Full Text]

57. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology. 2003; 228: 826–833.[Abstract/Free Full Text]

58. Schmermund A, Mohlenkamp S, Erbel R. Coronary artery calcium and its relationship to coronary artery disease. Cardiol Clin. 2003; 21: 521–534.[CrossRef][Medline] [Order article via Infotrieve]

59. Achenbach S. Clinical use of multi-slice CT coronary angiography. Herz. 2003; 28: 119–125.[CrossRef][Medline] [Order article via Infotrieve]

60. Kunimasa T, Sato Y, Sugi K, Moroi M. Evaluation by multislice computed tomography of atherosclerotic coronary artery plaques in non-culprit, remote coronary arteries of patients with acute coronary syndrome. Circ J. 2005; 69: 1346–1351.[CrossRef][Medline] [Order article via Infotrieve]

61. Fayad ZA, Fuster V, Fallon JT, Jayasundera T, Worthley SG, Helft G, Aguinaldo JG, Badimon JJ, Sharma SK. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation. 2000; 102: 506–510.[Abstract/Free Full Text]

62. Litovsky S, Madjid M, Zarrabi A, Casscells SW, Willerson JT, Naghavi M. Superparamagnetic iron oxide–based method for quantifying recruitment of monocytes to mouse atherosclerotic lesions in vivo: enhancement by tissue necrosis factor-alpha, interleukin-1beta, and interferon-gamma. Circulation. 2003; 107: 1545–1549.[Abstract/Free Full Text]

63. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol. 2006; 47: 1328–1338.[Abstract/Free Full Text]

64. Strauss HW, Dunphy M, Tokita N. Imaging the vulnerable plaque: a scintillating light at the end of the tunnel? J Nucl Med. 2004; 45: 1106–1107.[Free Full Text]

65. DeMaria AN, Narula J, Mahmud E, Tsimikas S. Imaging vulnerable plaque by ultrasound. J Am Coll Cardiol. 2006; 47: C32–39.[Abstract/Free Full Text]

66. Ishibashi F, Aziz K, Abela GS, Waxman S. Update on coronary angioscopy: review of a 20-year experience and potential application for detection of vulnerable plaque. J Intervent Cardiol. 2006; 19: 17–25.[CrossRef][Medline] [Order article via Infotrieve]

67. Low AF, Tearney GJ, Bouma BE, Jang IK. Technology Insight: optical coherence tomography: current status and future development. Nat Clin Pract Cardiovasc. 2006; 3: 154–162.[CrossRef]

68. Moreno PR, Muller JE. Detection of high-risk atherosclerotic coronary plaques by intravascular spectroscopy. J Interv Cardiol. 2003; 16: 243–352.[CrossRef][Medline] [Order article via Infotrieve]

69. Wilensky RL, Song HK, Ferrari VA. Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques. J Am Coll Cardiol. 2006; 47: C48–C56.[Abstract/Free Full Text]

70. Casscells W, Hathorn B, David M, Krabach T, Vaughn WK, McAllister HA, Bearman G, Willerson JT. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. Lancet. 1996; 347: 1447–1451.[CrossRef][Medline] [Order article via Infotrieve]

71. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA. 2005; 293: 855–862.[Abstract/Free Full Text]

72. Uchida Y, Nakamura F, Tomaru T, Morita T, Oshima T, Sasaki T, Morizuki S, Hirose J. Prediction of acute coronary syndromes by percutaneous coronary angioscopy in patients with stable angina. Am Heart J. 1995; 130: 195–203.[CrossRef][Medline] [Order article via Infotrieve]

73. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988; 12: 56–62.[Abstract]

74. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988; 78: 1157–1166.[Abstract/Free Full Text]

75. Ambrose JA, Winters SL, Arora RR, Haft JI, Goldstein J, Rentrop KP, Gorlin R, Fuster V. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol. 1985; 6: 1233–1238.[Abstract]

76. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol. 1986; 7: 472–478.[Abstract]

77. Levin DC, Fallon JT. Significance of the angiographic morphology of localized coronary stenoses: histopathologic correlations. Circulation. 1982; 66: 316–320.[Abstract/Free Full Text]

78. Waxman S, Mittleman MA, Zarich SW, Fitzpatrick PJ, Lewis SM, Leeman DE, Shubrooks SJ Jr, Abela GS, Nesto RW. Plaque disruption and thrombus in Ambrose’s angiographic coronary lesion types. Am J Cardiol. 2003; 92: 16–20.[CrossRef][Medline] [Order article via Infotrieve]

79. Kaski JC, Chester MR, Chen L, Katritsis D. Rapid angiographic progression of coronary artery disease in patients with angina pectoris: the role of complex stenosis morphology. Circulation. 1995; 92: 2058–2065.[Abstract/Free Full Text]

80. Haft JI, al-Zarka AM. Comparison of the natural history of irregular and smooth coronary lesions: insights into the pathogenesis, progression, and prognosis of coronary atherosclerosis. Am Heart J. 1993; 126: 551–561.[CrossRef][Medline] [Order article via Infotrieve]

81. Chester MR, Chen L, Tousoulis D, Poloniecki J, Kaski JC. Differential progression of complex and smooth stenoses within the same coronary tree in men with stable coronary artery disease. J Am Coll Cardiol. 1995; 25: 837–842.[Abstract]

82. Chester MR, Chen L, Kaski JC. The natural history of unheralded complex coronary plaques. J Am Coll Cardiol. 1996; 28: 604–608.[Abstract]

83. Lee SG, Lee CW, Hong MK, Kim JJ, Park SW, Park SJ. Change of multiple complex coronary plaques in patients with acute myocardial infarction: a study with coronary angiography. Am Heart J. 2004; 147: 281–286.[CrossRef][Medline] [Order article via Infotrieve]

84. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004; 110: 1747–1753.[Abstract/Free Full Text]

85. Goldstein JA, Chandra HR, O’Neill WW. Relation of number of complex coronary lesions to serum C-reactive protein levels and major adverse cardiovascular events at one year. Am J Cardiol. 2005; 96: 56–60.[CrossRef][Medline] [Order article via Infotrieve]

86. Ledru F, Theroux P, Lesperance J, Laurier J, Ducimetiere P, Guermonprez JL, Diebold B, Blanchard D. Geometric features of coronary artery lesions favoring acute occlusion and myocardial infarction: a quantitative angiographic study. J Am Coll Cardiol. 1999; 33: 1353–1361.[Abstract/Free Full Text]

87. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948–954.[Abstract/Free Full Text]

88. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101: 1899–1906.[Abstract/Free Full Text]

89. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002; 106: 653–658.[Abstract/Free Full Text]

90. Schindler TH, Hornig B, Buser PT, Olschewski M, Magosaki N, Pfisterer M, Nitzsche EU, Solzbach U, Just H. Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms. Arterioscler Thromb Vasc Biol. 2003; 23: 495–501.[Abstract/Free Full Text]

91. Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation. 2004; 109: 2518–2523.[Abstract/Free Full Text]

92. Okumura K. Yasue H. Matsuyama K. Ogawa H. Morikami Y Obata K Sakaino N. Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. J Am Coll Cardiol. 1992; 19: 752–758.[Abstract]

93. Movassaghi B, Rasche V, Grass M, Viergever MA, Niessen WJ. A quantitative analysis of 3-D coronary modeling from two or more projection images. IEEE Trans Med Imaging. 2004; 23: 1517–1531.[CrossRef][Medline] [Order article via Infotrieve]

94. Guedes A, Keller PF, L’Allier PL, Lesperance J, Gregoire J, Tardif JC. Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. J Am Coll Cardiol. 2005; 45: 559–564.[Abstract/Free Full Text]

95. Guedes A, Tardif JC. Intravascular ultrasound assessment of atherosclerosis. Curr Atheroscler Rep. 2004; 6: 219–224.[Medline] [Order article via Infotrieve]

96. Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation. 2001; 103: 604–616.[Abstract/Free Full Text]

97. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM, for the ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006; 354: 1253–1263.[Abstract/Free Full Text]

98. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM, for the ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295: 1556–1565.[Abstract/Free Full Text]

99. Tardif JC, Gregoire J, L’Allier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressler ML, Ibrahim R, Lesperance J, Blue J, Heinonen T, Rodes-Cabau J, for the Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004; 110: 3372–3377.[Abstract/Free Full Text]

100. Tardif JC. Antioxidants and atherosclerosis: emerging drug therapies. Curr Atheroscler Rep. 2005; 7: 71–77.[Medline] [Order article via Infotrieve]

101. Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol. 2001; 21: 1618–1622.[Abstract/Free Full Text]

102. Huang H, Virmani R, Younis H, Burke AP, Kamm RD, Lee RT. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation. 2001; 103: 1051–1056.[Abstract/Free Full Text]

103. Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, Nakamura Y, Yamashita H, Yamagishi H, Takeuchi K, Naruko T, Haze K, Becker AE, Yoshikawa J, Ueda M. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004; 110: 3424–3429.[Abstract/Free Full Text]

104. Burke AP, Weber DK, Kolodgie FD, Farb A, Taylor AJ, Virmani R. Pathophysiology of calcium deposition in coronary arteries. Herz. 2001; 26: 239–244.[CrossRef][Medline] [Order article via Infotrieve]

105. Gussenhoven EJ, Essed CE, Lancee CT, Mastik F, Frietman P, van Egmond FC, Reiber J, Bosch H, van Urk H, Roelandt J. Arterial wall characteristics determined by intravascular ultrasound imaging: an in vitro study. J Am Coll Cardiol. 1989; 14: 947–952.[Abstract]

106. Nishimura RA, Edwards WD, Warnes CA, Reeder GS, Holmes DR Jr, Tajik AJ, Yock PG. Intravascular ultrasound imaging: in vitro validation and pathologic correlation. J Am Coll Cardiol. 1990; 16: 145–154.[Abstract]

107. Yamagishi M, Terashima M, Awano K, Kijima M, Nakatani S, Daikoku S, Ito K, Yasumura Y, Miyatake K. Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol. 2000; 35: 106–111.[Abstract/Free Full Text]

108. Hiro T, Leung CY, De Guzman S, Caiozzo VJ, Farvid AR, Karimi H, Helfant RH, Tobis JM. Are soft echoes really soft? Intravascular ultrasound assessment of mechanical properties in human atherosclerotic tissue. Am Heart J. 1997; 133: 1–7.[CrossRef][Medline] [Order article via Infotrieve]

109. Prati F, Arbustini E, Labellarte A, Dal Bello B, Sommariva L, Mallus MT, Pagano A, Boccanelli A. Correlation between high frequency intravascular ultrasound and histomorphology in human coronary arteries. Heart. 2001; 85: 567–570.[Abstract/Free Full Text]

110. Kawasaki M, Takatsu H, Noda T, Ito Y, Kunishima A, Arai M, Nishigaki K, Takemura G, Morita N, Minatoguchi S, Fujiwara H. Noninvasive quantitative tissue characterization and two-dimensional color-coded map of human atherosclerotic lesions using ultrasound integrated backscatter: comparison between histology and integrated backscatter images. J Am Coll Cardiol. 2001; 38: 486–492.[Abstract/Free Full Text]

111. Murashige A, Hiro T, Fujii T, Imoto K, Murata T, Fukumoto Y, Matsuzaki M. Detection of lipid-laden atherosclerotic plaque by wavelet analysis of radiofrequency intravascular ultrasound signals in vitro validation and preliminary in vivo application. J Am Coll Cardiol. 2005; 45: 1954–1960.[Abstract/Free Full Text]

112. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation. 2002; 106: 2200–2206.[Abstract/Free Full Text]

113. Kawasaki M, Sano K, Okubo M, Yokoyama H, Ito Y, Murata I, Tsuchiya K, Minatoguchi S, Zhou X, Fujita H, Fujiwara H. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2005; 45: 1946–1953.[Abstract/Free Full Text]

114. Fujii K, Carlier SG, Mintz GS, Wijns W, Colombo A, Bose D, Erbel R, de Ribamar Costa J Jr, Kimura M, Sano K, Costa RA, Lui J, Stone GW, Moses JW, Leon MB. Association of plaque characterization by intravascular ultrasound virtual histology and arterial remodeling. Am J Cardiol. 2005; 96: 1476–1483.[CrossRef][Medline] [Order article via Infotrieve]

115. Rodriguez-Granillo GA, Serruys PW, Garcia-Garcia HM, Aoki J, Valgimigli M, van Mieghem CA, McFadden E, de Jaegere PP, de Feyter P. Coronary artery remodelling is related to plaque composition. Heart. 2006; 92: 388–391.[Abstract/Free Full Text]

116. Valgimigli M, Rodriguez-Granillo GA, Garcia-Garcia HM, Malagutti P, Regar E, de Jaegere P, de Feyter P, Serruys PW. Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasound study based radiofrequency data analysis in humans. Eur Heart J. 2006; 27: 655–663.[Abstract/Free Full Text]

117. Rodriguez-Granillo GA, Garcia-Garcia HM, Mc Fadden EP, Valgimigli M, Aoki J, de Feyter P, Serruys PW. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol. 2005; 46: 2038–2042.

118. Sano K, Kawasaki M, Ishihara Y, Okubo M, Tsuchiya K, Nishigaki K, Zhou X, Minatoguchi S, Fujita H, Fujiwara H. Assessment of vulnerable plaques causing acute coronary syndrome using integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2006; 47: 734–741.[Abstract/Free Full Text]

119. Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002; 106: 804–808.[Abstract/Free Full Text]

120. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation. 2004; 110: 928–933.[Abstract/Free Full Text]

121. Schoenhagen P, Stone GW, Nissen SE, Grines CL, Griffin J, Clemson BS, Vince DG, Ziada K, Crowe T, Apperson-Hanson C, Kapadia SR, Tuzcu EM. Coronary plaque morphology and frequency of ulceration distant from culprit lesions in patients with unstable and stable presentation. Arterioscler Thromb Vasc Biol. 2003; 23: 1895–1900.[Abstract/Free Full Text]

122. Tanaka A, Shimada K, Sano T, Namba M, Sakamoto T, Nishida Y, Kawarabayashi T, Fukuda D, Yoshikawa J. Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol. 2005; 45: 1594–1599.[Abstract/Free Full Text]

123. Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Dangas G, Moussa I, Mehran R, Lansky AJ, Kreps E, Collins M, Colombo A, Stone GW, Leon MB, Moses JW. Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. Circulation. 2003; 108: 2473–2478.[Abstract/Free Full Text]

124. Rioufol G, Gilard M, Finet G, Ginon I, Boschat J, Andre-Fouet X. Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound. Circulation. 2004; 110: 2875–2880.[Abstract/Free Full Text]

125. Hong MK, Mintz GS, Lee CW, Suh IW, Hwang ES, Jeong YH, Park DW, Kim YH, Han KH, Cheong SS, Kim JJ, Park SW, Park SJ. Serial intravascular ultrasound evidence of both plaque stabilization and lesion progression in patients with ruptured coronary plaques: effects of statin therapy on ruptured coronary plaque. Atherosclerosis. April 3, 2006. DOI: 10.1016/j.atherosclerosis.2006.02.040. Available at: http://www.sciencedirect.com. Accessed September 19, 2006.

126. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Eng J Med. 1987; 316: 1371–1375.[Abstract]

127. Smits PC, Pasterkamp G, Quarles van Ufford MA, Eefting FD, Stella PR, de Jaegere PP, Borst C. Coronary artery disease: arterial remodeling and clinical presentation. Heart. 1999; 82: 461–464.[Abstract/Free Full Text]

128. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation. 2000; 101: 598–603.[Abstract/Free Full Text]

129. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DP, Teepen H, van der Wal AC, Borst C. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000; 150: 245–253.[CrossRef][Medline] [Order article via Infotrieve]

130. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation. 2002; 105: 939–943.[Abstract/Free Full Text]

131. Pasterkamp G, Galis ZS, de Kleijn DP. Expansive arterial remodeling: location, location, location. Arterioscler Thromb Vasc Biol. 2004; 24: 650–657.[Abstract/Free Full Text]

132. Carlier S, Kakadiaris IA, Dib N, Vavuranakis M, O’Malley SM, Gul K, Hartley CJ, Metcalfe R, Mehran R, Stefanadis C, Falk E, Stone G, Leon M, Naghavi M. Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques. Curr Atheroscler Rep. 2005; 7: 164–169.[Medline] [Order article via Infotrieve]

133. Vavuranakis M, Kakadiaris IA, O’Malley SM, Stefanadis C, Vaina S, Drakopoulou M, Mitropoulos I, Carlier S, Naghavi M. Images in cardiovascular medicine: detection of luminal-intimal border and coronary wall enhancement in intravascular ultrasound imaging after injection of microbubbles and simultaneous sonication with transthoracic echocardiography. Circulation. 2005; 112: e1–e2.[Free Full Text]

134. Goertz DE, Frijlink ME, de Jong N, van der Steen AF. Nonlinear intravascular ultrasound contrast imaging. Euro Interv. 2006; 2: 132–142.

135. de Korte CL, van der Steen AF, Cespedes EI, Pasterkamp G. Intravascular ultrasound elastography in human arteries: initial experience in vitro. Ultrasound Med Biol. 1998; 24: 401–408.[CrossRef][Medline] [Order article via Infotrieve]

136. Schaar JA, De Korte CL, Mastik F, Strijder C, Pasterkamp G, Boersma E, Serruys PW, Van Der Steen AF. Characterizing vulnerable plaque features with intravascular elastography. Circulation. 2003; 108: 2636–2641.[Abstract/Free Full Text]

137. Schaar JA, Regar E, Mastik F, McFadden EP, Saia F, Disco C, de Korte CL, de Feyter PJ, van der Steen AF, Serruys PW. Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation. Circulation. 2004; 109: 2716–2719.[Abstract/Free Full Text]

138. Van Mieghem CA, McFadden EP, de Feyter PJ, Bruining N, Schaar JA, Mollet NR, Cademartiri F, Goedhart D, de Winter S, Granillo GR, Valgimigli M, Mastik F, van der Steen AF, van der Giessen WJ, Sianos G, Backx B, Morel MA, van Es GA, Zalewski A, Serruys PW. Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS). J Am Coll Cardiol. 2006; 47: 1134–1142.[Abstract/Free Full Text]

139. Feldman CL, Ilegbusi OJ, Hu Z, Nesto R, Waxman S, Stone PH. Determination of in vivo velocity and endothelial shear stress patterns with phasic flow in human coronary arteries: a methodology to predict progression of coronary atherosclerosis. Am Heart J. 2002; 143: 931–939.[CrossRef][Medline] [Order article via Infotrieve]

140. Stone PH, Coskun AU, Kinlay S, Clark ME, Sonka M, Wahle A, Ilegbusi OJ, Yeghiazarians Y, Popma JJ, Orav J, Kuntz RE, Feldman CL. Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study. Circulation. 2003; 108: 438–444.[Abstract/Free Full Text]

141. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA. 1999; 282: 2035–2042.[Abstract/Free Full Text]

142. Stone PH, Coskun AU, Yeghiazarians Y, Kinlay S, Wahle A, Sonka M, Popma JJ, Kuntz RE, Feldman CL Coronary plaque progresses in humans only in regions with endothelial shear stress <12 cynes/cm², but luminal encroachment depends primarily on inward remodeling. Am J Cardiol. 2004; 94: 121E.

143. Thieme T, Wernecke KD, Meyer R, Brandenstein E, Habedank D, Hinz A, Felix SB, Baumann G, Kleber FX. Angioscopic evaluation of atherosclerotic plaques: validation by histomorphologic analysis and association with stable and unstable coronary syndromes. J Am Coll Cardiol. 1996; 28: 1–6.[Abstract]

144. Blankenhorn DH. The infiltration of carotenoids into human atheromas and xanthomas. Ann Intern Med. 1960; 53: 944–954.[Abstract/Free Full Text]

145. Miyamoto A, Prieto AR, Friedl SE, Lin FC, Muller JE, Nesto RW, Abela GS 2nd. Atheromatous plaque cap thickness can be determined by quantitative color analysis during angioscopy: implications for identifying the vulnerable plaque. Clin Cardiol. 2004; 27: 9–15.[Medline] [Order article via Infotrieve]

146. Okamatsu K, Takano M, Sakai S, Ishibashi F, Uemura R, Takano T, Mizuno K. Elevated troponin T levels and lesion characteristics in non–ST-elevation acute coronary syndromes. Circulation. 2004; 109: 465–470.[Abstract/Free Full Text]

147. Mizote I, Ueda Y, Ohtani T, Shimizu M, Takeda Y, Oka T, Tsujimoto M, Hirayama A, Hori M, Kodama K. Distal protection improved reperfusion and reduced left ventricular dysfunction in patients with acute myocardial infarction who had angioscopically defined ruptured plaque. Circulation. 2005; 112: 1001–1007.[Abstract/Free Full Text]

148. Waxman S, Sassower MA, Mittleman MA, Zarich S, Miyamoto A, Manzo KS, Muller JE, Abela GS, Nesto RW. Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non-Q-wave myocardial infarction. Circulation. 1996; 93: 2106–2113.[Abstract/Free Full Text]

149. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992; 326: 287–291.[Abstract]

150. de Feyter PJ, Ozaki Y, Baptista J, Escaned J, Di Mario C, de Jaegere PP, Serruys PW, Roelandt JR. Ischemia-related lesion characteristics in patients with stable or unstable angina: a study with intracoronary angioscopy and ultrasound. Circulation. 1995; 92: 1408–1413.[Abstract/Free Full Text]

151. Nissen SE. Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist’s perspective. J Am Coll Cardiol. 2003; 41: 103S–112S.[Abstract/Free Full Text]

152. Takano M, Inami S, Ishibashi F, Okamatsu K, Seimiya K, Ohba T, Sakai S, Mizuno K. Angioscopic follow-up study of coronary ruptured plaques in nonculprit lesions. J Am Coll Cardiol. 2005; 45: 652–658.[Abstract/Free Full Text]

153. Rentrop KP. Thrombi in acute coronary syndromes: revisited and revised. Circulation. 2000; 101: 1619–1626.[Free Full Text]

154. Waxman S, Mittleman MA, Zarich SW, Fitzpatrick PJ, Lewis SM, Leeman DE, Shubrooks SJ Jr, Snyder JT, Muller JE, Nesto RW. Angioscopic assessment of coronary lesions underlying thrombus. Am J Cardiol. 1997; 79: 1106–1109.[CrossRef][Medline] [Order article via Infotrieve]

155. Mizuno K, Miyamoto A, Satomura K, Kurita A, Arai T, Sakurada M, Yanagida S, Nakamura H. Angioscopic coronary macromorphology in patients with acute coronary disorders. Lancet. 1991; 337: 809–812.[CrossRef][Medline] [Order article via Infotrieve]

156. Lehmann KG, Oomen JA, Slager CJ, deFeyter PJ, Serruys PW. Chromatic distortion during angioscopy: assessment and correction by quantitative colorimetric angioscopic analysis. Cathet Cardiovasc Diagn. 1998; 45: 191–201.[CrossRef][Medline] [Order article via Infotrieve]

157. Ueda Y, Ohtani T, Shimizu M, Hirayama A, Kodama K. Assessment of plaque vulnerability by angioscopic classification of plaque color. Am Heart J. 2004; 148: 333–335.[CrossRef][Medline] [Order article via Infotrieve]

158. Asakura M, Ueda Y, Yamaguchi O, Adachi T, Hirayama A, Hori M, Kodama K. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol. 2001; 37: 1284–1288.[Abstract/Free Full Text]

159. Tawakol A, Muller J. Through the looking glass: an angioscopic view of the effect of statin therapy on coronary artery plaques. J Am Coll Cardiol. 2003; 42: 687–689.[Free Full Text]

160. Takano M, Mizuno K, Yokoyama S, Seimiya K, Ishibashi F, Okamatsu K, Uemura R. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol. 2003; 42: 680–686.[Abstract/Free Full Text]

161. Tearney GJ, Jang IK, Bouma BE. Optical coherence tomography for imaging vulnerable plaque. J Biomed Opt. 2006; 11: 021002.[CrossRef][Medline] [Order article via Infotrieve]

162. Jang IK, Bouma BE, Kang DH, Park SJ, Park SW, Seung KB, Choi KB, Shishkov M, Schlendorf K, Pomerantsev E, Houser SL, Aretz HT, Tearney GJ. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol. 2002; 39: 604–609.[Abstract/Free Full Text]

163. Yabushita H, Bouma BE, Houser SL, Aretz HT, Jang IK, Schlendorf KH, Kauffman CR, Shishkov M, Kang DH, Halpern EF, Tearney GJ. Characterization of human atherosclerosis by optical coherence tomography. Circulation. 2002; 106: 1640–1645.[Abstract/Free Full Text]

164. Tearney GJ, Yabushita H, Houser SL, Aretz HT, Jang IK, Schlendorf KH, Kauffman CR, Shishkov M, Halpern EF, Bouma BE. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation. 2003; 107: 113–119.[Abstract/Free Full Text]

165. Stamper D, Weissman NJ, Brezinski M. Plaque characterization with optical coherence tomography. J Am Coll Cardiol. 2006; 47: C69–C79.[Abstract/Free Full Text]

166. Yun SH, Tearney GJ, de Boer JF, Iftima N, Bouma BE. High-speed optical frequency-domain imaging. Optics Express. 2003; 11: 2953–2963.[Medline] [Order article via Infotrieve]

167. Jang IK, Tearney GJ, MacNeill B, Takano M, Moselewski F, Iftima N, Shishkov M, Houser S, Aretz HT, Halpern EF, Bouma BE. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation. 2005; 111: 1551–1555.[Abstract/Free Full Text]

168. MacNeill BD, Jang IK, Bouma BE, Iftimia N, Takano M, Yabushita H, Shishkov M, Kauffman CR, Houser SL, Aretz HT, DeJoseph D, Halpern EF, Tearney GJ. Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J Am Coll Cardiol. 2004; 44: 972–979.[Abstract/Free Full Text]

169. Moreno PR, Muller JE. Identification of high-risk atherosclerotic plaques: a survey of spectroscopic methods. Curr Opin Cardiol. 2002; 17: 638–647.[CrossRef][Medline] [Order article via Infotrieve]

170. Jaross W, Neumeister V, Lattke P, Schuh D. Determination of cholesterol in atherosclerotic plaques using near infrared diffuse reflection spectroscopy. Atherosclerosis. 1999; 147: 327–337.[CrossRef][Medline] [Order article via Infotrieve]

171. Moreno PR, Lodder RA, Purushothaman KR, Charash WE, O’Connor WN, Muller JE. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation. 2002; 105: 923–927.[Abstract/Free Full Text]

172. Wang J, Geng YJ, Guo B, Klima T, Lal BN, Willerson JT, Casscells W. Near-infrared spectroscopic characterization of human advanced atherosclerotic plaques. J Am Coll Cardiol. 2002; 39: 1305–1313.[Abstract/Free Full Text]

173. Caplan JD, Waxman S, Nesto RW, Muller JE. Near-infrared spectroscopy for the detection of vulnerable coronary artery plaques. J Am Coll Cardiol. 2006; 47: C92–C96.[Abstract/Free Full Text]

174. Hasler-Rapacz J, Ellegren H, Fridolfsson AK, Kirkpatrick B, Kirk S, Andersson L, Rapacz J. Identification of a mutation in the low density lipoprotein receptor gene associated with recessive familial hypercholesterolemia in swine. Am J Med Genet. 1998; 76: 379–386.[CrossRef][Medline] [Order article via Infotrieve]

175. Brennan JF 3rd, Romer TJ, Lees RS, Tercyak AM, Kramer JR Jr, Feld MS. Determination of human coronary artery composition by Raman spectroscopy. Circulation. 1997; 96: 99–105.[Abstract/Free Full Text]

176. Romer TJ, Brennan JF 3rd, Fitzmaurice M, Feldstein ML, Deinum G, Myles JL, Kramer JR, Lees RS, Feld MS. Histopathology of human coronary atherosclerosis by quantifying its chemical composition with Raman spectroscopy. Circulation. 1998; 97: 878–885.[Abstract/Free Full Text]

177. Romer TJ, Brennan JF 3rd, Puppels GJ, Zwinderman AH, van Duinen SG, van der Laarse A, van der Steen AF, Bom NA, Bruschke AV. Intravascular ultrasound combined with Raman spectroscopy to localize and quantify cholesterol and calcium salts in atherosclerotic coronary arteries. Arterioscler Thromb Vasc Biol. 2000; 20: 478–483.[Abstract/Free Full Text]

178. Nogueira GV, Silveira L, Martin AA, Zangaro RA, Pacheco MT, Chavantes MC, Pasqualucci CA. Raman spectroscopy study of atherosclerosis in human carotid artery. J Biomed Opt. 2005; 10: 031117.[CrossRef][Medline] [Order article via Infotrieve]

179. van de Poll SW, Kastelijn K, Bakker Schut TC, Strijder C, Pasterkamp G, Puppels GJ, van der Laarse A. On-line detection of cholesterol and calcification by catheter based Raman spectroscopy in human atherosclerotic plaque ex vivo. Heart. 2003; 89: 1078–1082.[Abstract/Free Full Text]

180. Diamantopoulos L. Arterial wall thermography. J Interv Cardiol. 2003; 16: 261–266.[CrossRef][Medline] [Order article via Infotrieve]

181. Stefanadis C, Diamantopoulos L, Vlachopoulos C, Tsiamis E, Dernellis J, Toutouzas K, Stefanadi E, Toutouzas P. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: a new method of detection by application of a special thermography catheter. Circulation. 1999; 99: 1965–1971.[Abstract/Free Full Text]

182. Stefanadis C, Toutouzas K, Tsiamis E, Stratos C, Vavuranakis M, Kallikazaros I, Panagiotakos D, Toutouzas P. Increased local temperature in human coronary atherosclerotic plaques: an independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention. J Am Coll Cardiol. 2001; 37: 1277–1283.[Abstract/Free Full Text]

183. Ten Have AG, Draaijers EB, Gijsen FJ, Wentzel JJ, Slager CJ, Serruys PW, van der Steen AF. Influence of catheter design on lumen wall temperature distribution in intracoronary thermography. J Biomech. Published online before print April 5, 2006.

184. Stefanadis C, Toutouzas K, Tsiamis E, Mitropoulos I, Tsioufis C, Kallikazaros I, Pitsavos C, Toutouzas P. Thermal heterogeneity in stable human coronary atherosclerotic plaques is underestimated in vivo: the "cooling effect" of blood flow. J Am Coll Cardiol. 2003; 41: 403–408.[Abstract/Free Full Text]

185. Larose E, Yeghiazarians Y, Libby P, Yucel EK, Aikawa M, Kacher DF, Aikawa E, Kinlay S, Schoen FJ, Selwyn AP, Ganz P. Characterization of human atherosclerotic plaques by intravascular magnetic resonance imaging. Circulation. 2005; 112: 2324–2331.[Abstract/Free Full Text]

186. Correia LC, Atalar E, Kelemen MD, Ocali O, Hutchins GM, Fleg JL, Gerstenblith G, Zerhouni EA, Lima JA. Intravascular magnetic resonance imaging of aortic atherosclerotic plaque composition. Arterioscler Thromb Vasc Biol. 1997; 17: 3626–3632.[Abstract/Free Full Text]

187. Rogers WJ, Prichard JW, Hu YL, Olson PR, Benckart DH, Kramer CM, Vido DA, Reichek N. Characterization of signal properties in atherosclerotic plaque components by intravascular MRI. Arterioscler Thromb Vasc Biol. 2000; 20: 1824–1830.[Abstract/Free Full Text]

188. Zimmermann-Paul GG, Quick HH, Vogt P, von Schulthess GK, Kling D, Debatin JF. High-resolution intravascular magnetic resonance imaging: monitoring of plaque formation in heritable hyperlipidemic rabbits. Circulation. 1999; 99: 1054–1061.[Abstract/Free Full Text]

189. Botnar RM, Bucker A, Kim WY, Viohl I, Gunther RW, Spuentrup E. Initial experiences with in vivo intravascular coronary vessel wall imaging. J Magn Reson Imaging. 2003; 17: 615–619.[CrossRef][Medline] [Order article via Infotrieve]

190. Schneiderman J, Wilensky RL, Weiss A, Samouha E, Muchnik L, Chen-Zion M, Ilovitch M, Golan E, Blank A, Flugelman M, Rozenman Y, Virmani R. Diagnosis of thin-cap fibroatheromas by a self-contained intravascular magnetic resonance imaging probe in ex vivo human aortas and in situ coronary arteries. J Am Coll Cardiol. 2005; 45: 1961–1969.[Abstract/Free Full Text]

191. Regar E, Hennen B, Grube E, Halon D, Wilensky RL, Virmani R, Schneiderman J, Sax S, Friedmann H, Serruys PW, Wijns W. First in man application of a miniature self-contained intracoronary magnetic resonance imaging probe. a multi-center safety and feasibility trial. Euro Interv. In press.

192. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 1998; 97: 2433–2444.[Abstract/Free Full Text]

193. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu Rev Med. 1993; 44: 365–376.[CrossRef][Medline] [Order article via Infotrieve]

194. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, for the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267–1278.[CrossRef][Medline] [Order article via Infotrieve]

195. Schmermund A, Achenbach S, Budde T, Buziashvili Y, Forster A, Friedrich G, Henein M, Kerkhoff G, Knollmann F, Kukharchuk V, Lahiri A, Leischik R, Moshage W, Schartl M, Siffert W, Steinhagen-Thiessen E, Sinitsyn V, Vogt A, Wiedeking B, Erbel R. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation. 2006; 113: 427–437.[Abstract/Free Full Text]

196. Houslay E, Cowell SJ, Prescott R, Reid J, Burton J, Northridge DB, Boon NA, Newby DE. Progressive coronary calcification despite intensive lipid-lowering therapy: a randomised controlled trial. Heart. 2006; 92: 1207–1212.[Abstract/Free Full Text]

197. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002; 106: 2884–2887.[Abstract/Free Full Text]

198. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002; 8: 1257–1262.[CrossRef][Medline] [Order article via Infotrieve]

199. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001; 345: 1583–1592.[Abstract/Free Full Text]

200. Krasuski RA. HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. Curr Opin Lipidol. 2005; 16: 652–657.[Medline] [Order article via Infotrieve]

201. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002; 105: 2159–2165.[Abstract/Free Full Text]

202. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004; 350: 1505–1515.[Abstract/Free Full Text]

203. Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation. 2005; 111: 1847–1854.[Abstract/Free Full Text]

204. Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, Ageland H, Nilsson J. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994; 90: 1935–1941.[Abstract/Free Full Text]

205. Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B. High-dose recombinant apolipoprotein A-I (Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice: potential implications for acute plaque stabilization. Circulation. 2001; 103: 3047–3050.[Abstract/Free Full Text]

206. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003; 290: 2292–2300.[Abstract/Free Full Text]

207. Shah PK, Chyu KY. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc Med. 2005; 15: 291–296.[CrossRef][Medline] [Order article via Infotrieve]

208. Hallenbeck JM. Hansson GK. Becker KJ. Immunology of ischemic vascular disease: plaque to attack. Trends Immunol. 2005; 26: 550–556.[CrossRef][Medline] [Order article via Infotrieve]

209. Johnson A, Zalewski A, Janmohamed S, Sawyer J, Rolfe T, Staszkiewicz W, Alvarez S. Lipoprotein-associated phospholipase A2 activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: the results of a multicenter clinical study. Circulation. 2004; 110 (suppl III): III-590.

210. Kunsch C, Luchoomun J, Grey JY, Olliff LK, Saint LB, Arrendale RF, Wasserman MA, Saxena U, Medford RM. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent. J Pharmacol Exp Ther. 2004; 308: 820–829.[Abstract/Free Full Text]

211. Tardif JC, Gregoire J, Schwartz L, Title L, Laramee L, Reeves F, Lesperance J, Bourassa MG, L’Allier PL, Glass M, Lambert J, Guertin MC, for the Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation. 2003; 107: 552–558.[Abstract/Free Full Text]

212. Ambrose JA, D’Agate DJ. Classification of systemic therapies for potential stabilization of the vulnerable plaque to prevent acute myocardial infarction. Am J Cardiol. 2005; 95: 379–382.[CrossRef][Medline] [Order article via Infotrieve]

213. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006; 113: 1108–1113.[Abstract/Free Full Text]

214. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr, for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty), Society for Cardiac Angiography and Interventions. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation. 2001; 103: 3019–3041.[Free Full Text]

215. Fassa AA, Wagatsuma K, Higano ST, Mathew V, Barsness GW, Lennon RJ, Holmes DR Jr, Lerman A. Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: a long-term follow-up study. J Am Coll Cardiol. 2005; 45: 204–211.[Abstract/Free Full Text]

216. Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns W. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001; 103: 2928–2934.[Abstract/Free Full Text]

217. Malenka DJ, Leavitt BJ, Hearne MJ, Robb JF, Baribeau YR, Ryan TJ, Helm RE, Kellett MA, Dauerman HL, Dacey LJ, Silver MT, VerLee PN, Weldner PW, Hettleman BD, Olmstead EM, Piper WD, O’Connor GT, for the Northern New England Cardiovascular Disease Study Group. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. Circulation. 2005; 112 (suppl): I-371–I-376.[Medline] [Order article via Infotrieve]

218. Meier B, Ramamurthy S. Plaque sealing by coronary angioplasty. Cathet Cardiovasc Diagn. 1995; 36: 295–297.[Medline] [Order article via Infotrieve]

219. Meier B. Plaque sealing by coronary angioplasty. Heart. 2004; 90: 1395–1398.[Free Full Text]

220. Demidova TN, Hamblin MR. Photodynamic therapy targeted to pathogens. Int J Immunopathol Pharmacol. 2004; 17: 245–254.[Medline] [Order article via Infotrieve]

221. Hayase M, Woodbum KW, Perlroth J, Miller RA, Baumgardner W, Yock PG, Yeung A. Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model. Cardiovasc Res. 2001; 49: 449–455.[Abstract/Free Full Text]

222. Kereiakes DJ, Szyniszewski AM, Wahr D, Herrmann HC, Simon DI, Rogers C, Kramer P, Shear W, Yeung AC, Shunk KA, Chou TM, Popma J, Fitzgerald P, Carroll TE, Forer D, Adelman DC. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation. 2003; 108: 1310–1315.[Abstract/Free Full Text]

223. Waksman R, Leitch I, Roessler J, Yazdi H, Seabron R, Tio F, Scott RW, Grove RI, Rochnovsky S, Robinson B, Pakala R, Cheneau E. Intracoronary photodynamic therapy reduces neointimal growth without suppressing re-endothelialization in a porcine model. Heart. 2006; 92: 1138–1144.[Abstract/Free Full Text]

224. Tanguay JF, Geoffroy P, Dorval JF, Sirois MG. Percutaneous endoluminal arterial cryoenergy improves vascular remodelling after angioplasty. Thromb Haemost. 2004; 92: 1114–1121.[Medline] [Order article via Infotrieve]

225. Ruef J, Hofmann M, Haase J. Endovascular interventions in iliac and infrainguinal occlusive artery disease. J Interv Cardiol. 2004; 17: 427–435.[CrossRef][Medline] [Order article via Infotrieve]

226. Serruys PW, Hoye A, Grollier G, Colombo A, Symons J, Mudra H. A European multi-center trial investigating the anti-restenotic effect of intravascular sonotherapy after stenting of de novo lesions (EUROSPAH: European Sonotherapy Prevention of Arterial Hyperplasia). Int J Cardiovasc Intervent. 2004; 6: 53–60.[CrossRef][Medline] [Order article via Infotrieve]

227. Bosch JL, Beinfeld MT, Muller JE, Brady T, Gazelle GS. A cost-effectiveness analysis of a hypothetical catheter-based strategy for the detection and treatment of vulnerable coronary plaques with drug-eluting stents. J Interv Cardiol. 2005; 18: 339–349.[CrossRef][Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				K. C. Briley-Saebo, P. X. Shaw, W. J.M. Mulder, S.-H. Choi, E. Vucic, J. G. S. Aguinaldo, J. L. Witztum, V. Fuster, S. Tsimikas, and Z. A. Fayad Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes Circulation, June 24, 2008; 117(25): 3206 - 3215. [Abstract] [Full Text] [PDF]

				W. Q. Chen, L. Zhang, Y. F. Liu, L. Chen, X. P. Ji, M. Zhang, Y. X. Zhao, G. H. Yao, C. Zhang, X. L. Wang, et al. Prediction of atherosclerotic plaque ruptures with high-frequency ultrasound imaging and serum inflammatory markers Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2836 - H2844. [Abstract] [Full Text] [PDF]

				Y. S. Chatzizisis, A. U. Coskun, M. Jonas, E. R. Edelman, C. L. Feldman, and P. H. Stone Role of Endothelial Shear Stress in the Natural History of Coronary Atherosclerosis and Vascular Remodeling: Molecular, Cellular, and Vascular Behavior J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2379 - 2393. [Abstract] [Full Text] [PDF]

				G. A. Beller Noninvasive Screening for Coronary Atherosclerosis and Silent Ischemia in Asymptomatic Type 2 Diabetic Patients: Is it Appropriate and Cost-Effective? J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1918 - 1923. [Abstract] [Full Text] [PDF]

				J. S. Hochman and P. G. Steg Does Preventive PCI Work? N. Engl. J. Med., April 12, 2007; 356(15): 1572 - 1574. [Full Text] [PDF]

This Article Free upon publication Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waxman, S. Articles by Muller, J. E. Search for Related Content PubMed PubMed Citation Articles by Waxman, S. Articles by Muller, J. E. Related Collections Other arteriosclerosis